Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

Parkway

Parkway Minerals NL

Premium
Information Technology

Parkway Corporate is an Australian micro-cap that has moved from a failed potash explorer into a vertically integrated industrial water, wastewater and brine-processing group. It runs two linked divisions. Industrial Operations (Parkway Process Solutions, "PPS", including the acquired Tankweld business) sells water-treatment products and delivers engineering, fabrication, installation and structural-mechanical-piping (SMP) work to municipal, mining, energy and industrial clients. It generated record FY26 revenue of A$19.87M. Process Technologies (Parkway Process Technologies, "PPT", and Queensland Brine Solutions, "QBS") owns a proprietary portfolio led by the patented iBC® (integrated Brine Causticisation) and aMES® processes. These target conversion of regulated waste brines, principally from Queensland coal seam gas (CSG), into caustic soda, hydrochloric acid and other chemicals. The investment case depends on QBS's staged QBS Brine Management Complex (QBMC). QBMC received development approval on 20 August 2026, and the company quotes preliminary Stage 1 metrics of an IRR above 30% and a post-tax NPV above A$700M. The operating business is near break-even and carries a going-concern uncertainty flag. --- ### Company's own description (FY26 Annual Report, paraphrased) The FY26 Annual Report describes Parkway as an Australian water, wastewater treatment and process technology company. It says the company focuses on commercialising innovative process technologies in key industrial markets, which it sees as an effective way to address global water-related sustainability problems. In FY26 the company reported two principal activities: 1. **Process Technologies Division:** commercialisation of proprietary water, wastewater and brine-processing technologies, with applications in energy and mining. 2. **Industrial Operations Division:** conventional water and wastewater treatment products and services, including fabrication and project delivery (with installation), which supports the Process Technologies Division. Management states that as Industrial Operations scales, it becomes the delivery platform for commercialising PPT's technologies. Over FY26 the company says it built capability across the whole project lifecycle: process development, equipment selection, engineering, procurement, fabrication, installation and commissioning. ### Business model and revenue model | Revenue stream | Nature | Recognition basis (per accounting policy) | Approx. share of revenue | |---|---|---|---| | Water-treatment product sales (instrumentation, controllers, pipe/hose/fittings, valves, filters, membranes, tanks; PPS Digital online sales) | Product / distribution | Point in time, as invoiced; 30-day terms | NPD. PPS Digital passed A$1.0M trailing-12-month revenue in Q4-FY26 | | Engineering, fabrication, installation, SMP project execution (Tankweld) | Project services, fixed price or hourly rate | Over time, by milestone or percentage of completion | Majority of FY25–FY26 revenue (inferred from management commentary; exact split NPD) | | Technology services (feasibility studies, piloting, analytical testing, process development) | Technical services and consulting | Point in time / milestone | Small; e.g. about A$615k QGC (Shell) feasibility study, aMES piloting for a global miner | | Prospective: QBMC liquid-waste-management fees plus chemical sales | Infrastructure tolling plus commodity chemicals | Not yet earning | Nil today | | Prospective: PH-UHBCS modular systems with Hitachi; licensing | Equipment sales / licensing | Not yet earning | Nil today | There is no subscription revenue. Licensing has been discussed as a possible model for the CSG brine technology in the 2023 Master Plan but has not been contracted. ### Value-chain position Today Parkway is mainly a Tier-2 subcontractor and specialist supplier. Its flagship FY26 contract was SMP scope for a tier-1 engineering and construction contractor on one of Australia's largest municipal resource-recovery projects. The QBMC strategy would move it into asset ownership and operation: QBS would own and run a regulated waste facility that charges waste-management fees to CSG producers and sells chemicals made from the waste. That means moving from a low-margin service provider to an infrastructure-style owner. ### Customer types and end-markets The FY26 report lists municipal water authorities, major engineering contractors, energy companies (notably CSG/LNG), mining companies and other industrial clients. Named or identifiable counterparties include QGC Pty Limited (Shell Group), an unnamed tier-1 engineering contractor (about A$12.85M SMP contract), an unnamed global mining company (aMES piloting and an A$2M mine-dewatering contract), and Worley (strategic partner). All revenue is earned in Australia. ### Independent characterisation Parkway is best understood as a sub-scale engineering-and-fabrication contractor carrying an early-stage infrastructure development option. The operating business has grown fast (revenue up about 61x from FY21 to FY26). However, that growth came mostly from acquisitions (Multi-Wet, Mawpump, Tankweld) and one large contract. Margins have compressed as contracting mix rose: gross margin was 24.0% in FY26 against 31.6% in FY25. Statutory profitability has not been sustained: a maiden A$15,915 profit in FY25 was followed by a A$417,754 loss in FY26. The equity value depends overwhelmingly on QBMC. QBMC has strong regulatory tailwinds and now has primary approvals, but it has no funding, no binding offtake or brine-supply contracts disclosed, and no final investment decision. Against a market capitalisation of about A$30M, the gap between this and the company's own NPV claim reflects the market's discount for execution and financing risk.

RevenueN/A
Employees40
Market CapN/A
Founded2010
Victoria, Australia

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
ParagonCare

Paragon Care Limited

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Legal name | Paragon Care Limited | FY26 Appendix 4E | | Trading name | ParagonCare | FY25 Annual Report | | ABN / ACN | ABN 76 064 551 426 / ACN 064 551 426 | FY26 Appendix 4E; 1H26 Investor Presentation | | Former names | Not publicly disclosed in reviewed sources (no formal name change identified) | — | | Founding year (legacy Paragon Care) | 2008 (company "About" page) | paragoncare.com.au | | Founding year (CH2 / Clifford Hallam lineage) | 1918 ("We started out in Australia in 1918") | FY25 Annual Report | | Incorporation jurisdiction | Australia (Corporations Act 2001) | FY25 Annual Report, Note 1 | | Registered office & principal place of business | 77–97 Ricketts Road, Mount Waverley, VIC 3149, Australia | FY25 Annual Report, Note 1 | | Exchange / ticker | Australian Securities Exchange — PGC (secondary listing: Deutsche Börse ticker PXS, per Fintel) | ASX; Fintel | | ISIN | AU000000PGC4 | Fintel | | CUSIP | Not applicable / not publicly disclosed (Australian issuer) | — | | Fiscal year end | 30 June | Annual reports | | Employees | 1,292 (FY25); "over 1,200" cited in FY25 Chair/CEO letter; FY24 and FY23 combined-group figures not publicly disclosed | FY25 Annual Report | | Gender split (FY25) | 51% male / 49% female | FY25 Annual Report | | Auditor | Ernst & Young (Melbourne; FY25 lead partner Paul Gower) | FY25 Annual Report; FY26 Appendix 4E | | Share registry | Not re-verified for FY26 (FY22: Link Market Services) | FY22 Annual Report | | Shares on issue | 1,655,305,389 (weighted average FY25 and FY26; ~1.66bn) | FY26 Appendix 4E, Part 17 | | Share price (latest verified) | A$0.135 (4 Sep 2026); A$0.13–0.135 range Jul–Sep 2026. | InvestSMART | | Market capitalisation | ≈A$223m at A$0.135 (1,655.3m shares) | InvestSMART; calculation | | CEO & MD | Carmen Riley (CEO from 1 Jul 2025; MD from 1 Mar 2026) | ASX announcements 25 Jun 2025, 25 Feb 2026 | | Chair | Peter Lacaze | FY25 Annual Report | | Website | https://www.paragoncare.com.au | — | The entity on the user's list (Paragon Care Limited, ASX: PGC, Australia) remains the same listed legal entity. Its trading name is now styled "ParagonCare". The website on the list (paragoncare.com.au) is current. No change of ticker or exchange has occurred. The economic business, however, is now dominated by the former Clifford Hallam Healthcare (CH2) pharmaceutical wholesale business following the June 2024 reverse acquisition. ParagonCare is a mid-sized, founder-controlled Asia-Pacific healthcare distributor that combines a high-volume, thin-margin Australian pharmaceutical wholesale engine (inherited from Clifford Hallam Healthcare, Australia's only independent Community Service Obligation wholesaler) with a portfolio of higher-margin specialty businesses: medical technology agencies (imaging, devices, orthopaedics, robotics, vision, aesthetics, dental), third-party healthcare contract logistics, and TGA-certified clinical manufacturing of red-cell blood-bank reagents. FY26 revenue was A$3.68bn, but underlying EBITDA of A$97.2m represents a margin of only ~2.6%, and 96% of revenue still comes from Australia and New Zealand. Strategy is pivoting toward Asia, where six bolt-on acquisitions in FY26 lifted segment revenue 58% to A$160m at ~42% gross margin. The equity story is constrained by a A$38.0m credit loss on the collapsed Infinity Pharmacy Group, a statutory FY26 loss, leverage of ~2.5x, negative net tangible assets, no dividend, and a share price that has fallen roughly 60–70% from its post-merger implied level. --- ### Company's own description The FY25 Annual Report and FY26 Appendix 4E describe ParagonCare as one of Asia Pacific's leading diversified healthcare distributors and manufacturers, delivering pharmaceuticals, capital equipment, diagnostics, medical consumables, devices and complementary medicines, with origins in Australia in 1918 and a "transformational" 2024 merger of Clifford Hallam and ParagonCare. Its stated purpose is to make healthcare simpler, smarter and more accessible across Asia Pacific, and its vision is to be the region's most trusted and efficient diversified healthcare distribution and manufacturing partner (FY25 Annual Report). The statutory principal-activities description (FY25 Directors' Report; FY26 Appendix 4E Part 8) is: supply of durable medical equipment, medical devices, consumable medical products and maintenance of technical medical equipment to the health, aged care (and aesthetics/veterinary) markets throughout Australia, New Zealand and Asia, plus distribution of pharmaceuticals, medical consumables and complementary medicines to the Australian healthcare market. ### Go-to-market structure (four channels) | Channel | Business units | Core customers | |---|---|---| | Wholesale | Pharmacy; Medical Consumables; Complementary Medicines (Oborne, ParagonCare Prescribe); Dental Supplies (incl. AHP Dental) | Independent retail pharmacies, non-affiliated and affiliated pharmacy groups (incl. second-line wholesaling), public and private hospitals, aged care, primary care, allied health, naturopaths/TCM practitioners, dental clinics | | Medical Technology | OEM Capital (imaging, PACS); OEM Devices (infusion, oncology, neonatal, surgical, critical care, urology); Vision; Aesthetics; Surgical Implants/Orthopaedics; Surgical Robotics (CMR Surgical); Service | Public/private hospitals, day surgeries, orthopaedic surgeons, optometrists/ophthalmologists, dermatologists/cosmetic clinics, imaging departments | | Contract Logistics | 3PL/4PL services for healthcare suppliers (e.g., Owens & Minor from June 2025; Pacific Medical in Hong Kong from Feb 2026) | Pharmaceutical and medtech manufacturers, public health distribution centres, pharmaceutical wholesalers | | Clinical Manufacturing | Immulab red-cell reagent manufacturing; contract manufacturing (first agreement FY25); diagnostic instruments & consumables distribution; Fisher Biotec (acquired Jan 2026) | Pathology labs, blood banks, IVF clinics, microbiology labs, universities, hospitals | Following a FY25 restructuring, the group operates through four go-to-market channels supported by shared services (Finance, IT, Marketing, Customer Service, Supply Chain, Commercial, Procurement): (Source: FY25 Annual Report, "Business Focus" and "Customer Networks" pages; FY26 Results Release.) ### Revenue model and value-chain position | Revenue type (A$m) | FY25 | FY26 | |---|---|---| | Goods (point in time) | 3580.1 | 3652.3 | | Services (over time) | 33.8 | 28.3 | | Total revenue | 3613.9 | 3680.5 | | Supplier rebates (memo) | 417.2 | 450.9 | The revenue model is overwhelmingly product resale (point-in-time recognition). In FY26, goods transferred at a point in time were A$3,652.3m (99.2%) and services transferred over time were A$28.3m (0.8%), versus A$3,580.1m and A$33.8m in FY25 (FY26 Appendix 4E, Part 9). There is no material subscription or licensing revenue. Supplier rebates are a critical economic lever: rebates of A$450.9m in FY26 (A$417.2m in FY25) offset a gross cost of inventories sold of A$3,787.8m, meaning rebates are larger than the group's entire gross margin (A$347.5m) (FY26 Appendix 4E, Part 9b). ParagonCare sits in the mid-stream distribution layer of the healthcare value chain: it buys from originator and generic pharmaceutical manufacturers, global medtech OEMs (for which it often holds exclusive regional agency rights) and private-label sources, and sells to pharmacies, hospitals and clinics. Upstream, it manufactures a narrow line of in-vitro diagnostic reagents (Immulab) and offers contract manufacturing. Sideways, it monetises its warehouse network by providing contract logistics to other suppliers. ### Independent characterisation Economically, ParagonCare is two businesses wearing one ticker: 1. A scale-dependent ANZ pharmaceutical and consumables wholesaler (Wholesale channel ≈A$3.0bn of FY25 revenue, ≈82% of group) operating at a channel margin of ~6.0–6.3% (FY26 Results Release) and ANZ segment margin of ~8.0%, competing against far larger incumbents (EBOS/Symbion, Sigma/Chemist Warehouse, Wesfarmers Health/API). This business generates revenue mass, supplier rebates and CSO funding but very little operating profit after warehouse, freight and finance costs. 2. A specialty distribution and manufacturing portfolio (MedTech ~39–41% channel margin, Clinical Manufacturing ~44–46%, Asia ~42–46%) that likely produces the majority of group gross profit dollars outside wholesale, and which is the explicit focus of capital allocation. The credit event with Infinity Pharmacy Group (a Priceline franchisee) illustrates the principal structural risk of the wholesale model: very large receivable exposures to individual pharmacy groups relative to the group's thin equity cushion. ### End-markets served Retail community pharmacy (independent and banner groups), hospital pharmacy (public and private), acute hospitals (capital, devices, implants), aged care and community care, primary care and allied health, dental, aesthetics/dermatology, optometry/ophthalmology, pathology/blood banking, IVF, defence (5-year Australian Defence Force supply contract from Q4 FY26), and B2B logistics for healthcare manufacturers. Geographic end-markets: Australia, New Zealand, Thailand, South Korea, Japan, Philippines, Vietnam, and (via FY26 acquisitions) Singapore, Malaysia, Indonesia, Hong Kong/Macau. The 1H26 presentation cites a presence in nine Asian countries.

Revenue$2.4B
Employees1,292
Market CapN/A
Founded2008
Mount Waverley, Australia
Paradigm

Paradigm Biopharmaceuticals Limited

Premium
Information Technology

Paradigm Biopharmaceuticals is a Melbourne-based, pre-revenue drug-repurposing company that spent more than a decade developing a single molecule — pentosan polysulfate sodium (PPS), an old semi-synthetic polysaccharide derived from beech-wood xylan — as a subcutaneous injection (iPPS, branded Zilosul®) for knee osteoarthritis pain and function. The thesis was that a six-week course of injections could deliver a durable, non-opioid benefit positioned between conservative care and knee replacement, with possible structural (cartilage and bone-marrow-lesion) effects as differentiation. The company held US FDA Fast Track designation, ran a TGA Special Access Scheme generating token revenue, and in 2025 added an oral PPS-plus-COX-2 combination (Pentacoxib®) through the acquisition of Proteobioactives. Its fate was binary on the pivotal PARA_OA_012 trial. The September 2026 futility outcome, combined with secured convertible note obligations and thin net assets, pushed the company into voluntary administration, where its residual value now lies in IP, clinical data and any recapitalisation. --- **Company's own description (paraphrased from FY2026 Annual Report).** Paradigm describes itself as a late-stage clinical development company whose purpose is to improve patients' health and quality of life by developing and delivering pharmaceutical therapies, with a vision of becoming a recognised global leader in developing and commercialising innovative therapies. Its stated principal activity is researching and developing therapeutic products for human use. Its standard boilerplate describes the current focus as developing iPPS for diseases in which inflammation plays a major pathogenic role, drawing on the anti-inflammatory and tissue-regenerative properties attributed to PPS, with osteoarthritis at Phase 3. **Independent characterisation.** Paradigm was, in substance, a single-asset, single-indication repurposing biotech. PPS has a long history as an approved oral product (in some markets for interstitial cystitis) and as a veterinary injectable; Paradigm's proprietary angle was the subcutaneous human formulation, dose regimen (2 mg/kg twice weekly for six weeks), method-of-use patents, and a clinical dataset in knee OA. Third-party commentary notes that Germany's Bene Pharmachem was the sole manufacturer of the active ingredient, creating supply concentration (Stockhead, 2023). **Business model.** Development-stage licensing/commercialisation model. Management's stated plan was to generate Phase 3 evidence, file an NDA with the FDA, and pursue regional and global licensing (discussions at BIO International Convention 2026). No commercial product approval was ever obtained. **Revenue model mix (FY2026).** Roughly 99% of reported income is non-operating (R&D Tax Incentive and interest). Product, service, subscription and licensing revenue: none, other than SAS access fees. **Value chain position.** Clinical development sponsor. Manufacturing of API outsourced (Bene Pharmachem per press commentary); clinical operations outsourced to Advanced Clinical (global CRO) and Nordic Bioscience Clinical Development A/S (complementary CRO for imaging, biomarkers, Hong Kong and Moldova expansion). **Customer types and end-markets.** Prospective: physicians (rheumatology, orthopaedics, sports medicine, primary care) treating symptomatic knee OA; payers; pharma licensing partners. Current: a small number of experienced Australian prescribers under SAS (including chronic arthralgia from Ross River virus infection). Pentacoxib® was initially targeted at veterinary applications.

RevenueN/A
Employees50
Market CapN/A
Founded2014
Melbourne, Australia
Pancontinental

Pancontinental Oil & Gas NL

Premium
Information Technology

Pancontinental Energy NL is a Perth-based, single-asset-dominant frontier oil explorer. Its value rests almost entirely on a 75% operated interest in Petroleum Exploration Licence 87 (PEL 87) in Namibia's Orange Basin. The basin has become one of the most consequential deepwater oil provinces of the decade, following TotalEnergies' Venus, Shell's Graff, Galp's Mopane and Azule/Rhino's Capricornus discoveries. Woodside fully funded a 6,593 km² 3D seismic survey (around US$35–38m) and then declined to farm in, in March 2025. Since then Pancontinental has independently matured an eight-target inventory with an arithmetic-sum High Case (3U) of about 8.2 billion barrels gross (6.1 billion net), recoverable, unrisked. The company carries no debt, holds about A$2.4m cash and is run by a lean team of five people. Its investment case is binary: whether it can secure a funded farm-in partner to drill PEL 87 within a licence term now extended to 22 January 2027. --- ### Company's own description (paraphrased from the FY2025 Annual Report) The FY2025 Directors' Report describes Pancontinental's principal activities as energy exploration. This covers managing offshore acreage, reviewing and assessing seismic data, conducting technical studies and assessing new venture opportunities. The company calls itself a junior energy exploration company whose activities depend on acquiring, evaluating and advancing high-impact offshore exploration projects. It identifies the following as the decisive business drivers: - disciplined working-capital management - technical capability - the ability to secure and keep quality acreage - strategic partnerships and farm-outs The Board lists five objectives: 1. advance the offshore Namibian permit 2. maximise value from the asset portfolio 3. secure complementary new ventures 4. manage technical, financial and operational risk 5. preserve liquidity ### Business model and revenue model Pancontinental generates no operating revenue. It has no product, service, subscription or licensing income. Its "revenue" line is interest and foreign-exchange income only: A$178,149 in FY2025 and A$54,250 in FY2024 (Directors' Reports). The business model is the classic "prospect generator / farm-out" model used by junior explorers: 1. **Acquire frontier acreage cheaply**, often as first mover with a local partner and the national oil company (NAMCOR in Namibia). 2. **Add technical value** using low-cost data, such as 2D seismic reprocessing, basin modelling and quantitative interpretation. 3. **Farm out** to a larger company, which funds high-cost work (3D seismic, drilling) in exchange for equity. Pancontinental is carried and may receive past-cost reimbursements or option fees. 4. **Monetise** through a discovery-driven re-rating, partial sell-down, retained carried equity, or conversion into a royalty. The Woodside Option Deed (March 2023) is the template. Woodside paid US$1.5m and fully funded a 3D survey, in exchange for an exclusive option over 56% of PEL 87. Had it exercised, Woodside would have carried the joint venture through the first well, and Pancontinental would have kept 20% (FY2024 Annual Report). ### Value-chain position Pancontinental sits at the extreme upstream end of the oil and gas value chain: frontier exploration (pre-discovery). It has no appraisal, development, production, midstream or downstream exposure. Its potential "customers" are effectively: **Farminees:** international oil companies and large independents seeking deepwater acreage. **Acquirers:** corporate buyers of the licence interest or of the company. **Equity investors:** who fund the corporate overhead. ### End markets The ultimate end market is global crude oil (and possibly associated gas). Its relevance is indirect: oil price expectations shape farm-in appetite and capital-market sentiment towards explorers. The proximate "market" is the market for deepwater exploration acreage in the Atlantic margin, particularly Namibia's Orange Basin. ### Independent characterisation Pancontinental is best characterised as a listed option on a single deepwater licence. The company has a small non-core earning interest in two onshore Queensland permits (ATP 920/924), whose renewals are pending. It has also lodged an early-stage New Zealand permit application (2026). Neither is material to valuation. The equity behaves like a call option: **Payoff drivers:** farm-in terms (who funds the well and what carry Pancontinental keeps) and drill outcome. **Time decay:** the licence term, now 22 January 2027, with a drilling commitment attached. **Funding cost:** dilution risk if no partner arrives. Overhead discipline is a genuine strength; quarterly operating cash burn runs at about A$0.3–0.4m. Governance is weak by ASX Principles standards (no independent directors), which matters for a company that may soon negotiate a transformational farm-out.

RevenueN/A
Employees3
Market CapN/A
Founded1985
effective Apr, Australia
PallaPharma

Palla Pharma Limited

Premium
Information Technology

Palla Pharma, founded as TPI Enterprises by Jarrod Ritchie, was an Australian vertically integrated opiate manufacturer. It spanned the chain from contracted poppy cultivation and poppy-straw processing through to codeine phosphate active pharmaceutical ingredient (API) and tableted finished dosage forms (FDF). It was one of three licensed poppy processors in Australia and the only Australian-owned one. It described itself as one of six licensed opiate producers globally and one of three fully integrated suppliers from extraction to tableting. Its claimed differentiator was a proprietary, water-based alkaloid extraction process that it said was low-cost, needed a small workforce and was environmentally sustainable. From 2017 the company pursued a "move down the value chain" strategy. It acquired Vistin Pharma's Norwegian opiates and tableting business and later bought UK marketing authorisations so it could sell its own branded generics. Collapsing volumes, low opioid prices, COVID-driven cuts to elective surgery and rising losses led to administration in December 2021 and liquidation in 2022. --- **Company's own description (FY2020 annual report and 2020 ASX announcements).** Palla Pharma described itself as a vertically integrated opiate manufacturer, from poppy straw through to tableting production. It said it had developed an innovative, efficient and environmentally sustainable opiate manufacturing process based on a novel water-based extraction technology. It called itself one of six licensed opiate producers globally and one of three fully integrated suppliers from opiate extraction to tableting. Data providers summarise the business as producing and distributing narcotic raw materials (NRM), APIs and FDF for pharmaceutical markets in Australia and Norway, plus poppy seed for culinary markets. **Independent characterisation.** Palla was a sub-scale, capital-intensive commodity alkaloid processor trying to become a specialty generic-drug manufacturer. Its economic engine had three stages: 1. **Upstream (Australia, Coolaroo, Victoria).** Poppy straw was sourced from contracted growers in Australia and the Northern Hemisphere (the company referred to "Australian and Northern Hemisphere supply sources" and had grower contracts in Portugal). The straw was processed into NRM, an alkaloid-rich concentrate mainly of morphine and codeine. By-product poppy seed was sold into culinary markets. 2. **Midstream (Norway, Kragerø).** NRM was shipped from Melbourne to the Kragerø plant and converted into codeine phosphate API and pholcodine (a cough-suppressant opioid). The plant had come with the 2017 Vistin acquisition. 3. **Downstream (Norway, Kragerø, and the UK market).** API was granulated and tableted into finished dosage forms. These were sold first as contract manufacturing for third parties, and from 2020–21 under Palla-owned UK marketing authorisations (MAs) such as a 30/500 co-codamol caplet. **Revenue model.** Almost entirely product sales. The mix was NRM and poppy seed (B2B commodity), API (B2B supply contracts, typically multi-year with minimum tonnages), contract tableting (CMO), and own-MA FDF sales to UK wholesalers. There was no subscription or licensing revenue of note. One FY2020 disclosure referred to the termination of a "non-opiate based supply agreement", meaning lower-margin non-opiate contract work had also existed, probably legacy Vistin CMO tableting. **Value-chain position.** Palla was a supplier to generic-drug formulators, contract manufacturers and, through its own MAs, UK pharmaceutical wholesalers. Customers included "one of Europe's leading pharmaceutical contract manufacturing organisations" (2018 contract), an unnamed European codeine phosphate customer (2019), a major UK-based multinational (2020 tablet extension), Sterling Pharma Solutions (UK, 2016 manufacturing and supply deal), an unnamed "global pharmaceutical company" (A$30 million deal, 2016), and Weifa (Norway, inherited from the Vistin CMO business). **End markets.** Prescription and over-the-counter analgesics (codeine and co-codamol), cough and cold (pholcodine, codeine linctus), and culinary poppy seed. Demand was tied to surgical volumes and acute pain prescribing, which is why COVID-related elective-surgery cancellations, particularly in the UK, became the proximate trigger for failure.

Revenue$0.0B
Employees60
Market CapN/A
Founded2004
Melbourne, Australia
Paladin

Paladin Energy Ltd

Premium
Information Technology

Paladin Energy is a mid-tier, pure-play uranium producer and developer whose investment case rests on two Tier-1-calibre assets in two of the world's most established uranium jurisdictions. In Namibia it owns 75% of the Langer Heinrich Mine (LHM), a conventional open-pit/heap-free tank-leach operation restarted in March 2024 after six years on care and maintenance, which completed its ramp-up in FY2026 with 4.82Mlb U3O8 produced and US$304.3M of sales revenue. China National Nuclear Corporation (via CNNC Overseas Uranium Holding) holds the remaining 25%. In Canada, the December 2024 acquisition of Fission Uranium delivered the Patterson Lake South (PLS) project in Saskatchewan's Athabasca Basin—a shallow, high-grade development asset with a 9.1Mlb/yr design, environmental approval received February 2026, and first production targeted for 2031. Paladin is therefore one of the few Western-aligned, multi-jurisdiction uranium vehicles combining near-term cash flow with a large-scale growth project, positioned to benefit from a structurally tightening term market. --- **What the company does.** Paladin explores for, develops, mines, processes and sells uranium oxide concentrate (U3O8, "yellowcake"). Its only revenue-generating asset is the Langer Heinrich Mine in the Erongo region of Namibia. The company sells U3O8 to nuclear utilities and other fuel-cycle participants under a portfolio of long-term contracts (base-escalated, fixed-price and market-related mechanisms) supplemented by occasional spot sales, and uses uranium product loan facilities for delivery flexibility (400,000lb outstanding at 30 June 2026 per the June 2026 Quarterly Report). **Company's own description (FY2026 Results Overview, "About Paladin"):** Paladin describes itself as a globally significant independent uranium producer with a 75% ownership of the long-life Langer Heinrich Mine; in Canada it is progressing development of the Tier-1, high-grade, shallow PLS Project and holds exploration assets in the Athabasca Basin and the Michelin project in Newfoundland and Labrador; in Australia it holds uranium exploration assets in Queensland and Western Australia. It frames LHM as supplying major nuclear utilities around the world and PLS as supporting future global nuclear expansion. **Business model and revenue model.** **Value chain position.** Paladin is an upstream "front-end" participant: mining and milling to U3O8. It does not participate in conversion, enrichment or fuel fabrication. Its product is delivered to converter accounts on behalf of utility customers. **Customer types.** Nuclear utilities (North America, Europe, Asia) and fuel-cycle intermediaries/traders. Customer names and regional split are not publicly disclosed in reviewed sources. CNNC, as 25% LHM owner, has historically held offtake entitlements proportionate to its interest (detail of current arrangements not publicly disclosed in reviewed sources). **Contract book.** At the 2026 Investor Day (2 Sep 2026), 56% of contracted volumes for 2026–2030 were described as market-related, giving the company meaningful exposure to price upside while the balance (base-escalated/fixed) provides floor protection. **End-markets served.** Civil nuclear power generation (baseload electricity), including incremental demand from reactor life extensions, new-build programmes, and the emerging small modular reactor (SMR) and data-centre power-supply segment. **Independent characterisation.** Paladin is now a "producer with a development option": a single-asset cash generator (LHM) of modest margin at current cost levels (FY2026 cost of production US$43.3/lb vs. realised price US$70.0/lb, before depreciation, royalties, stripping, G&A) funding exploration and pre-development of a far superior asset (PLS: AISC US$15.2/lb per the Aug-2025 Engineering Review). The share price is driven far more by uranium term-price expectations and PLS de-risking than by LHM's current earnings. The company's medium-term challenge is to finance a US$1.226bn PLS build while keeping LHM reliable after a reputation-damaging FY2025 guidance failure.

Revenue$0.3B
EmployeesN/A
Market CapN/A
Founded1993
Perth, Australia
Zirax

Zirax Limited

Premium
Information Technology

| Attribute | Detail | Source | |---|---|---| | Legal name profiled | Zirax Limited (England & Wales, company no. 05533825) | Companies House | | Former names | Zirax plc (11 Aug 2005 – 11 Mar 2010) | Companies House, previous names | | Current status | Dissolved 27 Jun 2023 (voluntary strike-off; DS01 filed 3 Apr 2023; First Gazette 11 Apr 2023) | Companies House filing history | | Listing status (historical) | AIM, London Stock Exchange. Admitted 16 Dec 2005; de-listed by early 2010 (the board was reconstituted 23 Feb 2010 and the company re-registered as private by 11 Mar 2010) | AIM Admission Document (12 Dec 2005); Companies House | | Listing status (current) | Not listed. Privately held | Companies House | | ISIN (historical) | GB00B0T9VS23 | AIM Admission Document 2005 | | CUSIP | n/d (not applicable to the UK AIM line) | — | | Ticker | n/d | — | | Founding year | Operating business: 7 Feb 2002 (OOO Global-Kaustik). UK holdco: 11 Aug 2005 | AIM Admission Document 2005 | | Incorporation jurisdiction | England & Wales (holdco). Russian Federation (operating company) | Companies House; EGRUL via OpenSanctions | | Registered office (last) | 14 Old Queen Street, London SW1H 9HP (from 21 Mar 2018; previously 8 Clifford Street, London W1S 2LQ; at IPO 51 Eastcheap, London EC3M 1JP) | Companies House | | Operating HQ / plant | OOO "Zirax", ul. 40 let VLKSM 57I, Volgograd 400097 (earlier: mkr. 4, d. 6, Svetly Yar, Volgograd oblast) | EGRUL via OpenSanctions | | SIC (UK holdco) | 64209 – Activities of other holding companies n.e.c. | Companies House | | Fiscal year end | 31 December (final period extended to 30 Jun 2022) | Companies House (AA01, 22 Nov 2022) | | Employees | Operating company: 8 (Dec 2002), 19 (Dec 2003), 28 (Dec 2004), 49 (Sep 2005). Current group headcount n/d. A UK commercial database lists the holdco at 1 employee | AIM Admission Document 2005; GlobalDatabase | | Auditor | PricewaterhouseCoopers LLP (reporting accountant/auditor at IPO, 2005). Later auditors n/d | AIM Admission Document 2005 | | Market capitalisation | At IPO: £25.85m (172,321,429 shares × 15p). Current: not applicable (unlisted, dissolved) | AIM Admission Document 2005 | | Website | zirax.com (UK/international); zirax.ru (Russia) | Company websites | | Ultimate controlling persons (last filed) | Mikhail Baranov and Eldor Azizov, each holding more than 25% but not more than 50% (notified 6 May 2022) | Companies House PSC register | The input names "Zirax Limited" as a public company. Registry research shows that this classification is out of date. The entity profiled here is the London-incorporated holding company of the Zirax calcium-chloride and specialty-chemicals group, which operates from Volgograd in Russia. It was listed on the London Stock Exchange's AIM market as Zirax plc from December 2005 until it de-listed and re-registered as a private company in early 2010. The UK holding company itself was dissolved by voluntary strike-off on 27 June 2023. The operating business continues through the Russian company OOO "Zirax" (Volgograd). A UK trading company that kept the brand, Zirax (UK) Limited, also remains active. The table below states which entity each data point refers to. Zirax is a vertically integrated Russian producer of synthetic, high-purity calcium chloride (CaCl₂) and the products derived from it. It sells oilfield brine and drilling additives (PelletOil, MaxOil, SomaxOil), municipal and retail de-icers (IceMelt, CleanCity, IceBlaze), food-grade E509 calcium chloride (Fudix) and industrial grades (Unipell). Through its majority-owned NPO NIIPAV it also sells surfactants. The business started in 2002 as a joint venture with the chlor-alkali producer Kaustik and operates inside the Volgograd chemical park, where it uses Kaustik's by-product hydrochloric acid. It floated on AIM in 2005, raising £7.75m, and returned to private ownership in 2010 under the shareholders who also control the NIKOCHEM group. Zirax describes itself as the world's second-largest supplier of calcium chloride pellets and the leading supplier in the Eastern Hemisphere. It also licenses fluid-bed pelletising technology, for example to TCI Sanmar's 135 ktpa plant in Egypt. Its exposure is concentrated in Russia, so sanctions, rouble movements and municipal tender cycles dominate its risk profile. --- ### What the company does At its 2005 IPO, Zirax described itself as the UK holding company of Global-Kaustik, a Russian company engaged in research and development, production, marketing and sale of calcium-chloride-based specialty chemicals. Its two core products were calcium chloride and "calcium chloride modified natrium", a CaCl₂/NaCl blend sold for de-icing. At that time the three commercial applications were: 1. Oilfield process chemicals under the PelletOil brand. 2. High-performance de-icers under the IceMelt and CleanCity brands, plus private label for Benick Brands in North America. 3. Other industrial uses. *(Source: AIM Admission Document, 12 Dec 2005, Part I.)* The company's international website currently describes Zirax in three ways: - An oilfield chemicals producer and service organisation that develops production and stimulation chemicals and CaCl₂-based brines for drilling, completion and workover. - An integrated CaCl₂ producer of technical, food, road and drilling grades at 96–98% purity. - An engineering company offering to engineer, build and operate CaCl₂ plants, from liquid to pellets. Services include pre-engineering studies, basic engineering, training and offtake. *(Source: zirax.com home page, accessed Oct 2026.)* Zirax's Russian careers profile describes a broader chemistry base. It covers synthetic calcium, magnesium and sodium chlorides, calcium carbonate, and synthetic acids and their derivatives. Oilfield services are delivered jointly with the affiliate Zirax-Nefteservice. *(Source: Habr Career company profile, 2026.)* An industry review by IMARC describes five production areas: oil and gas solutions, de-icing, industrial solutions, food additives and surfactants. *(Source: IMARC Group, "Top Calcium Chloride Companies".)* ### Business and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Revenue model | Predominantly product sales (bulk and packaged chemicals). A secondary technology licensing / engineering services stream has existed since at least 2016 | Admission Document 2005; TCI Sanmar / Nuberg announcements, Sep 2016 | | Product vs. service vs. licensing mix | Not publicly disclosed after 2005. In FY2004 the business was effectively 100% product (PelletOil 34%, CleanCity 41%, IceMelt 20%, other 5%) | Admission Document 2005 | | Value-chain position | Mid-stream converter. It buys hydrochloric acid (a chlor-alkali by-product) and limestone, converts them into CaCl₂ solution, and dries the solution into pellets in fluid-bed towers. Final products are sold to oilfield service companies, municipalities, retailers, food processors and industrial users | Admission Document 2005, §7–8 | | Customer types | Tier-1 and Tier-2 oilfield service companies (e.g., Halliburton, Baker Hughes; distributor Cal-Chlor); Moscow municipal road-maintenance enterprises; North American home-improvement retail via Benick Brands; food processors (cheese, brewing, canning) | Admission Document 2005 | | End-markets | Oil and gas drilling and completion; winter road maintenance; food and beverages; construction (concrete acceleration); water treatment; home and personal care (surfactants) | Admission Document 2005; zirax.com 2018; NIIPAV product listings | | Seasonality | High. De-icer sales are winter-weighted and municipal tenders are awarded annually. Cash-flow gaps were flagged as a risk at IPO | Admission Document 2005, Risk Factors | ### Independent characterisation Zirax is best understood as a niche, high-purity CaCl₂ pelletiser attached to a Russian chlor-alkali complex (Kaustik / NIKOCHEM). Its cost advantage came from three sources: captive, low-cost hydrochloric acid supplied under long-term contract, cheap Russian gas and power, and proprietary fluid-bed drying know-how that yields 94–98% CaCl₂ pellets. Few producers worldwide make pellets rather than flake. *(Admission Document 2005, §6.)* Since the 2010 de-listing, the group has diversified in four directions: food-grade CaCl₂ (Fudix), surfactants (via NIIPAV), oilfield brine systems and services (via Zirax-Nefteservice), and technology export. Public disclosure has nonetheless become very thin.

Revenue$0.0B
Employees49
Market CapN/A
Founded2002
United States, North America
Zibo

Zibo Qixiang Tengda Chemical Co., Ltd.

Premium
Information Technology

Qixiang Tengda is China's leading independent C4 (four-carbon hydrocarbon) deep-processing chemical company, and is increasingly also a C3 (propane/propylene) producer. It converts refinery and cracker by-product streams into a flexible slate of solvents, rubber monomers, polymers and intermediates. Its anchor franchise is methyl ethyl ketone (MEK, butanone). The company describes its 260 kt/yr MEK capacity as the largest in China and in the world. Around this core sit maleic anhydride, butadiene made by butene oxidative dehydrogenation, butadiene rubber, nitrile latex, MMA, MTBE and tert-butanol. Since 2023 a 700 kt/yr propane dehydrogenation (PDH) unit has fed downstream propylene oxide (HPPO route) and acrylic acid capacity. A catalyst subsidiary, Qilu Keli, and a lower-margin international trading arm round out the group. After the 2022–2024 collapse of its former private parent (the Cedar/Xuesong group) and a court-led restructuring, the company has been controlled by Shandong Energy Group, one of China's largest provincial SOEs. Group revenue for FY2025 was CNY 23.8bn, and the company has been near breakeven-to-loss at the bottom of the chemical cycle. --- ### Company's own description (FY2025 annual report, paraphrased) Management describes the business as stable and organised around two pillars: chemical manufacturing and international trade. Its main products include MEK, maleic anhydride, propylene, rubber, butadiene, MMA, nitrile latex, tert-butanol, MTBE, propylene oxide, acrylic acid and a range of petroleum and chemical catalysts. Within manufacturing, management frames the company as a C4 specialist built on four "pivots": butene, isobutene, n-butane and isobutane. These streams pass through cracking, separation, conversion and refining, and then branch through oxidation, polymerisation and etherification routes. The resulting products are sold into solvents, synthetic rubber, artificial marble/unsaturated polyester, fuel additives and electronic chemicals. A C3 chain has been added along a propane → propylene → propylene oxide path, with acrylic acid and butyl acrylate as further derivatives. Management stresses that the plants are designed flexibly, so feedstock and product allocation can switch between chains as margins move. ### Independent characterisation Qixiang Tengda is a mid-cap, commodity-to-semi-specialty petrochemical processor with these characteristics: **Feedstock-spread economics:** Earnings are driven by the spread between purchased C4/C3 feedstocks (mixed C4, n-butane, propane) and the realised prices of its products. Revenue is overwhelmingly product sales, with no meaningful subscription, licensing or service income. Catalysts sold by Qilu Keli are the closest thing to a technical-product business. **Mid-stream position:** The company sits between the refiners and crackers that supply its C4/C3 streams (including Sinopec Qilu in the same Zibo industrial cluster, plus imported LPG/propane for PDH) and downstream converters. Those converters include coatings, adhesives, ink, synthetic leather, tyres, gloves, PMMA/acrylic sheet, polyurethane foam, unsaturated polyester resin and super-absorbent polymer producers. **Trade arm:** The international trade segment adds roughly 35–37% of revenue at gross margins of about 2–3%. It inflates the top line, contributes little profit, and consumes working capital. **Customer types:** The customers are industrial B2B buyers: domestic and overseas chemical converters, distributors and traders. No single-customer concentration is disclosed in the sources reviewed. **End-markets:** These are coatings and inks, adhesives, synthetic leather, electronics cleaning, tyres and rubber goods, nitrile gloves, PMMA and optical/display materials, polyurethanes (furniture, autos), gasoline blending, and refinery/coal-chemical catalysts. Many are construction- and consumer-cyclical, and management explicitly cites property-linked demand weakness in FY2025. ### Revenue model mix (FY2025) | Revenue type | FY2025 revenue (CNY M) | Share of total | Gross margin | Source | |---|---|---|---|---| | Chemical manufacturing (product sales) | 14694 | 61.8% | 4.74% | FY2025 AR via Lixinger | | International trade | 8840 | 37.2% | 2.13% | FY2025 AR via Lixinger | | Other / other operating revenue | 236 | 1.0% | n/d | Derived residual (total less segments) | | Services / subscription / licensing | 0 | 0% | — | Not a disclosed revenue line |

Revenue$3.3B
Employees3,460
Market CapN/A
Founded2002
Shandong Province, China
Zhejiang

Zhejiang Runtu Co., Ltd.

Premium
Information Technology

Zhejiang Runtu is one of China's two largest textile-dye manufacturers, alongside Zhejiang Longsheng, and by its own disclosure ranks in the top two by domestic dye market share. With roughly 238,000 tonnes of annual dye capacity — 118,000 t of disperse dyes for polyester, 100,000 t of reactive dyes for cotton and cellulosics, and ~20,000 t of other dye classes — Runtu supplies China's printing-and-dyeing industry, which absorbs over 93% of sales. Its strategic differentiator is a decade-long "backward integration" programme that links captive heat-and-power, steam, chlor-alkali, hydrogen peroxide, sodium hydrosulfite, chlorobenzene/nitrochlorobenzene chains and key intermediates (notably the disperse-dye intermediate "reduction product") to finished dye. This insulates margins during intermediate price shocks such as the 2026 supply crunch. Family-controlled, debt-light (net cash ~CNY 2 bn), and historically a high-payout dividend payer, Runtu is now also generating material financial returns from equity stakes in semiconductors and fluorochemicals. --- ### Company's own description (paraphrased from H1 2026 Interim Report) The company states that it is principally engaged in the research, development, production and sale of textile dyes, printing-and-dyeing auxiliaries and chemical raw materials. It reports total dye capacity of nearly 238,000 t/yr (disperse 118,000 t; reactive 100,000 t; other dyes ~20,000 t) and a sales market share that ranks it in the top two of the domestic dye market. Beyond dyes it operates 50,000 t/yr of sodium hydrosulfite (保险粉, a dyeing auxiliary), 160,000 t/yr of caustic soda (100% basis), 90,000 t/yr of hydrogen peroxide, 90,000 t/yr of chlorobenzene and nitrochlorobenzene-type products, and 8,000 t/yr of the disperse-dye intermediate "reduction product" (2-amino-4-acetamidoanisole). The company describes an independent R&D, production and sales model; a production system that combines make-to-order for customised products with make-to-stock for standard grades; opportunistic over-procurement of raw materials when prices are cyclically low; and fully independent domestic and export sales channels. ### Independent characterisation Runtu is best understood as a vertically integrated, commodity-to-specialty colourant producer whose earnings are dominated by the dye price cycle. Approximately three-quarters of revenue (H1 2026: 74.2%) comes from dyes; a further ~19% comes from "other chemical raw materials" — essentially the merchant surplus of its integration chain (caustic soda, hydrogen peroxide, chlorinated aromatics, sulphuric-acid-chain products) — which often carries a higher gross margin than dyes themselves (H1 2026: 34.9% vs 26.5%). Auxiliaries (chiefly sodium hydrosulfite) are a small residual line (1.8%). **Business model mechanics:** **Revenue model:** ~100% product sales (point-in-time revenue recognition at delivery for domestic sales; at customs clearance/shipment for exports). Leasing income is immaterial (CNY 0.99 M in H1 2026). There is no subscription, licensing or service revenue of significance. **Value-chain position:** Mid-stream specialty chemicals. Upstream inputs are benzene derivatives, nitration feedstocks, coal/steam, salt (for chlor-alkali) and naphthalene-based intermediates (e.g., H-acid for reactive dyes). Downstream customers are printing and dyeing mills (textile finishers), dye traders/compounders and, to a lesser extent, export distributors. **Pricing:** The company describes a "price-following" strategy — dye prices are set by market supply/demand and raw-material costs, and Runtu tracks the market rather than leading it (IR record, 30 Jun 2026). In practice, as one of two oligopolists with captive intermediates, Runtu's price moves are closely watched by the industry. **Customer base:** Highly fragmented. The top five receivable counterparties at 30 Jun 2026 accounted for only 13.94% of trade receivables, with the largest single debtor at 4.14% (H1-26 IR). This implies low customer-concentration risk but meaningful credit-management workload (bad-debt provisions of CNY 120.9 M against gross receivables of CNY 2,002.9 M). **End markets:** Polyester textiles and polyester blends (disperse dyes), cotton/viscose/cellulosic textiles (reactive dyes), wool/nylon/acrylic and blends (other dye classes), digital textile printing inks (via subsidiary Zhejiang Runhua Digital Printing), plus industrial chemical users of caustic soda, hydrogen peroxide and chlorinated aromatics. **Geography:** Overwhelmingly domestic (H1 2026: 93.5% domestic, 6.5% export). ### Revenue mix (latest disclosure — H1 2026) | Product line | Revenue H1 2026 (CNY M) | Share of revenue (%) | Gross margin (%) | YoY revenue growth (%) | |---|---|---|---|---| | Dyes | 2660.9 | 74.23 | 26.52 | 48.30 | | Auxiliaries | 64.3 | 1.79 | 12.87 | -30.90 | | Other chemical raw materials | 676.0 | 18.86 | 34.89 | 9.73 | | Other (other business) | 183.7 | 5.12 | 30.67 | -9.28 | | Total | 3584.9 | 100.00 | 28.06 | 32.49 | Source: H1-26 IR (segment tables); "Other" gross margin per Great Wall Securities note (Aug 2026). Total gross margin derived: (3,584.9 − 2,578.8) / 3,584.9.

Revenue$0.8B
Employees3,762
Market CapN/A
Founded1986
Shaoxing, China
Zhejiang

Zhejiang Pengfu New Materials Co., Ltd.

Premium
Information Technology

Pfluon is a privately held Chinese specialty-polymer company. It is built around two capabilities that are rare in combination: - A leading domestic franchise in fluoropolymer and ceramic non-stick coatings for cookware and small appliances, run by the Quzhou subsidiary profiled here. - Captive synthesis of polyaryletherketone (PAEK) resins, chiefly PEEK, at Jinhua. The coatings business competes head-on with multinationals such as Chemours and Daikin in pans, air fryers and rice-cooker bowls. It has historically generated most of the profit pool, with segment gross margins above 40% in 2019–H1 2022. The PEEK business is smaller and lower-margin, at roughly 25–29% gross margin. It gives the Group an option on high-growth end markets: semiconductor consumables, aerospace composites, medical implants and humanoid-robot lightweighting. The Group's strategic arc runs from a coatings formulator toward an integrated "high-performance polymer platform". It is anchored by an 18,000-tonne "future factory" broken ground in late 2022 and by a second attempt at an A-share listing. --- **Company's own description.** The Group says it has spent many years focused on developing and manufacturing special polymers and related application products. Its core products are special engineering plastics, special coatings and biomaterials. Its stated ambition is to become a world-class polymer materials enterprise. It lists seven application fields: aerospace, automotive, home appliances and cookware, electronics and semiconductors, petrochemicals, clean energy, and medical devices. (Pfluon website "Company Profile", accessed Oct 2026; paraphrased.) In its January 2024 tutoring filing, as reported by Securities Times, the Group described itself as a developer, manufacturer and seller of high-performance polymers and derivatives, with two product series: **special coatings:** - polyarylether resins **Independent characterisation.** Economically, Pfluon is a B2B specialty-chemicals manufacturer with an almost entirely product-based revenue model. There is no disclosed service, subscription or licensing revenue. It sits in the mid-stream of the value chain: **Upstream inputs:** fluoropolymer dispersions and resins (PTFE, PFA, FEP), solvents, pigments and fillers for coatings; aromatic monomers (e.g., difluorobenzophenone and hydroquinone, the standard PEEK route) for resins. **What Pfluon makes:** formulated coatings and polymerised resin/powder. **Customers:** convert these into finished goods — coated cookware, appliance parts, moulded or machined PEEK parts, prepreg tapes, implants. **Customer types:** 1. Cookware and small-appliance OEMs and coating applicators. This is the core of the special-coatings business; the end products are non-stick pans, air fryers, electric grills and rice-cooker inner pots. 2. Compounders, moulders and stock-shape producers buying PEEK resin and powder. 3. Composite manufacturers buying ultrafine PEEK powder for continuous-fibre prepreg tapes (promoted at Chinaplas 2026). 4. Semiconductor-consumables makers (wafer carriers, CMP retaining rings), per Group technical articles of June 2026. 5. Medical-device makers, targeted through the implant-grade PEEK programme funded under the 13th Five-Year Plan. **Revenue mix (latest disclosed, 2019–H1 2022).** A segment revenue split was not published in the press coverage. However, the margin data and management commentary indicate that special coatings were the larger and higher-margin business. - Main-business gross margin declined from 42.50% (2019) to 37.17% (H1 2022). Source: ChiNext application data as reported by STCN. - Special coatings gross margin: 44.33% → 40.75%. - Polyarylether resin gross margin: 28.59% → 27.93%, with a trough of 25.40% in 2020. **Regulatory and qualification moat in coatings.** Food-contact coatings must clear stringent safety tests. The Group reports that its coatings have passed: - US FDA testing - California Proposition 65 testing - German LFGB food-contact testing They also comply with REACH and RoHS (STCN, Jan 2024). The Group has also commercialised a low-VOC, organic-solvent-free waterborne coating platform. A related PCT application, WO2023010997 (priority 6 Aug 2021), covers a low-VOC, solvent-free, heat-resistant waterborne paint and the high-temperature, corrosion-resistant coating made from it (PitchBook patent record).

Revenue$0.1B
Employees169
Market CapN/A
Founded2006
Jinhua, China
Zhejiang

Zhejiang Longsheng Group Co., Ltd.

Premium
Information Technology

Zhejiang Longsheng is the world's largest producer and service provider of textile chemicals. It has 330,000 tonnes per year of operating dye capacity (430,000 t/y approved), 80,000 t/y of textile auxiliaries and 119,500 t/y of dye intermediates. The group combines a Chinese commodity-scale disperse and reactive dye base with DyStar, the former Bayer/Hoechst/BASF dye business that became wholly owned in January 2026. That gives Longsheng a global brand, a technical-service network and specialty know-how that domestic peers lack. Its main competitive advantage is backward integration into scarce, hazardous intermediates. These include reduction product (3-amino-4-methoxyacetanilide), m-phenylenediamine, resorcinol and H-acid, which make up 60–80% of dye production cost and face tight regulatory limits on new capacity. A second, non-core business holds a large Shanghai real-estate portfolio (Huaxing New Town, Hongkou). That property business inflated revenue volatility in 2022–24 and still ties up a large inventory balance. Longsheng is therefore an integrated specialty-chemicals cyclical with a property tail and a very high dividend payout. --- ### The company's own description In its periodic reports, Longsheng describes two core businesses: 1. **Textile chemicals**, led by dyes and auxiliaries. 2. **Intermediates**, led by m-phenylenediamine (间苯二胺) and resorcinol (间苯二酚). Real estate is reported separately as an "other/real estate" activity (China Securities Journal summary of the Q1 2026 report, 1 May 2026). The FY2025 annual report and the 2026 interim report describe a "vertical extension" strategy. Under it, the company moves from a single dye business into the wider specialty-chemicals field. It concentrates on core intermediates (resorcinol, p-phenylenediamine, m-aminophenol) and related products such as reduction product. ### Independent characterisation Longsheng is best understood as three economic engines with very different capital intensity, cyclicality and cash profiles. **(a) Integrated dye manufacturing (≈55% of FY2025 revenue).** The group produces disperse dyes for polyester, reactive dyes for cotton and cellulosics, and a smaller range of acid, sulphur, vat and other dyes. These are sold mainly as powders and liquids to textile dye houses. The domestic business (Longsheng-branded, Zhejiang-based) is commodity-like and moves with Chinese dye prices. DyStar adds premium branded ranges (Dianix, Levafix, Remazol, Sera auxiliaries, Cadira sustainability systems). It also brings colour-management services (Colour Solutions International / Econfidence) and brand-owner relationships with global apparel retailers. **(b) Intermediates (≈22% of FY2025 revenue).** The group makes benzene- and naphthalene-chain intermediates for its own use and for sale. These are m-phenylenediamine (65 kt/y), reduction product (20 kt/y, the world's largest supplier), H-acid (20 kt/y), resorcinol and others. Resorcinol and m-phenylenediamine also go to tyre-rubber adhesion, aramid fibre, UV absorbers and agrochemical markets. Intermediates were the main profit driver in H1 2026, with a 39.56% gross margin. They give the group pricing power when regulators shut smaller, hazardous capacity. **(c) Real estate and other (≈6% real estate plus ≈7% auxiliaries/other in FY2025).** The main asset is the Huaxing New Town (华兴新城) redevelopment in Hongkou, Shanghai. It contains for-sale residential units (the "湾上 Wanshang" high-rise, due for handover at end-2026) and held-for-rent apartments and offices, which carry an investment-property balance of CNY 12.7 billion at end-2025. Real-estate revenue is lumpy and is recognised on handover. It fell 67% in FY2025 to CNY 814M. ### Revenue model | Revenue model component | Share of FY2025 revenue | Notes | |---|---|---| | Product sales – dyes | ~55% (7,278) | Volume × ASP; ASP CNY 30,057/t in FY2025 | | Product sales – intermediates | ~22% (2,864) | Includes inter-segment volumes sold externally | | Product sales – auxiliaries | ~7% (939) | DyStar and domestic auxiliaries | | Real estate sales and rental | ~6% (814) | Recognised on handover; rental recurring | | Other (inorganic chemicals, etc.) | ~10% (balance) | Includes sulphuric acid, by-products and trading | | Subscription / licensing | Not material | No separate disclosure | Revenue is almost entirely product sales. Services such as colour-management and technical support, and rental income, are small and not separately disclosed. Pricing is spot or short-contract in the domestic market and based on price lists and contracts at DyStar. Shares are derived from segment figures against total revenue of CNY 13,313M (FY2025 Annual Report, via Great Wall Securities and Guosen). ### Value-chain position and customers Longsheng sits in the middle of the chain, from petrochemical aromatics to the textile dye house. It is integrated upstream, from benzene/naphthalene through intermediates to dyes. Customers include: **Chinese printing and dyeing mills:** These are concentrated in Zhejiang (Shaoxing/Keqiao), Jiangsu, Fujian and Guangdong. **International dye houses:** in Bangladesh, Vietnam, India, Turkey, Pakistan, Indonesia and Latin America, served mainly through DyStar. - **Global apparel and footwear brands**, which specify DyStar products and sustainability systems. - **Industrial buyers of intermediates**, including tyre/rubber, aramid, agrochemical and pharmaceutical producers. **Property buyers and tenants:** in Shanghai. End-markets are apparel, home textiles, technical textiles, tyres, high-performance fibres and Shanghai residential and commercial property.

Revenue$1.9B
Employees5,327
Market CapN/A
Founded1970
Zhejiang Province, China
Zeon

Zeon Corporation

Premium
Information Technology

Zeon is a mid-cap Japanese specialty chemicals company. It started as Japan's first PVC and synthetic-rubber producer and has since repositioned itself as a "Polymer Design Company." Its core technical asset is a pair of proprietary C4/C5 fraction extraction processes: - GPB (butadiene extraction) - GPI (isoprene and cyclopentadiene extraction) These processes supply monomers into two portfolios: **Elastomer Business:** Nipol® NBR, Zetpol® HNBR, S-SBR, acrylic rubber, latex and C5 resins. **Specialty Materials Business:** ZEONEX®/ZEONOR® cyclo-olefin polymer (COP), ZeonorFilm® retardation films, lithium-ion battery binders, semiconductor etching gases and solvents. Elastomers still generate about 54% of sales, but Specialty Materials earned 18% operating margins in FY2025 and about 60% of segment profit. Under the STAGE30 plan (Phase 3, FY2025–FY2028), management is: - concentrating ¥170bn of committed growth capex on COP, optical films, battery materials, DCPD feedstock and single-walled carbon nanotubes; - exiting non-core and low-return units (medical devices, paints, NBR latex); - reducing cross-shareholdings; - lifting shareholder returns via a DOE-based dividend policy. --- ### Company self-description In its filings and presentations, Zeon describes itself as a specialty chemicals maker. Its distillation and purification technologies, GPB and GPI, are characterized in the securities report as world-class. These processes are the starting point for a family of high-value products: - HNBR - cyclo-olefin polymers - optical films - battery materials The company frames its identity as a "Polymer Design Company," expressed through a Will/Can/Need model: **Will:** the corporate philosophy, "Contributing to the preservation of the Earth and the prosperity of the human race." **Can:** polymer-related skills. **Need:** five materiality "gears." This identity is set out in the 10 June 2026 Phase 3 status deck. ### Independent characterization Zeon is best understood as a monomer-integrated, mid-stream polymer and specialty materials producer. It buys C4 and C5 cracker fractions from Japanese naphtha crackers and extracts high-purity monomers (butadiene, isoprene, cyclopentadiene/DCPD). Some of this monomer is used in-house; the rest is sold. Value is captured at three levels: **(1) Commodity-adjacent elastomers.** Products include general-purpose SBR/BR, NBR latex and C5 petroleum resins. Margins here are thin (3–5%) and pricing follows naphtha and Asian butadiene through formula pass-through. **(2) Specialty elastomers.** Products include HNBR (Zetpol®), acrylic rubber, specialty NBR and high-grade S-SBR for fuel-efficient tyres. Zeon describes itself as a world leader in specialty rubber, a position built on the specialty elastomer business transferred from B.F. Goodrich. **(3) Engineered specialty materials.** This tier earns the highest returns: - COP resin for smartphone and automotive lenses, prefilled syringes/vials and semiconductor wafer carriers - COP-based retardation films for LCD TVs and mobile displays - binders and separator adhesives for lithium-ion batteries - polymerized toner - semiconductor etching gases (C5F8, ZEORORA®) and specialty solvents - aroma chemicals ### Revenue model | Revenue model element | Share / status (FY2025) | Comment | |---|---|---| | Product sales (materials) | ~99%+ (estimate not disclosed; implied by segment composition) | Formula-priced elastomers; contract/spec-priced specialty materials | | Services | Minor | Microfluidic prototyping (Edge Precision), transcriptome analysis (Zeon BioSolutions, est. Oct 2025), IT services (ZIS Information Technology, consolidated from FY2026) | | Subscription | Nascent | Elastomer formulation data management system (~150,000 formulation records), launched as Zeon's first subscription service in FY2026 (July 2026 press release) | | Licensing | Not separately disclosed | Historical technology licensing (e.g., a vaccine technology license, pre-2015) | Revenue is almost entirely product sales: bulk chemicals, compounds, resins, films and formulated binders. ### Value-chain position, customers and end-markets | End-market | Products | Exposure commentary | |---|---|---| | Automotive | Specialty rubbers (HNBR, ACM, NBR), S-SBR, RIM products, COP lenses for cameras/sensors, battery binders | Largest single end-market for Elastomers | | Displays / consumer electronics | ZeonorFilm® retardation films (large TV, tablet, smartphone), COP optical lenses | About 40% of Specialty Plastics; large-TV share gains in FY2025 | | Semiconductors | COP for wafer containers, etching gases, CPN solvent, electronic materials | Tied to fab construction in China and Taiwan and to AI memory/logic | | Energy storage | Anode/cathode binders, separator adhesives, SWCNT | Shift from EV to ESS (AI data-centre BBU, grid) noted FY2025–Q1 FY2026 | | Medical & life science | COP for prefilled syringes/vials, microplates (Aurora), microfluidics (Edge, ex-Ushio), latex for gloves | Medical devices business being transferred to Kaneka | | Industrial / adhesives | C5 petroleum resins (Quintone®), SIS, thermoplastic elastomers | Weak overseas tape/label demand FY2025 | | Fragrance | Leaf alcohol, aroma chemicals | Chinese competition compressing prices | **Upstream inputs:** - naphtha-cracker C4 and C5 fractions - acrylonitrile - styrene - utilities FY2025 benchmark inputs: Asian butadiene averaged US$1,157/t and naphtha ¥65,600/kL (FY2025 deck). **Downstream customers:** - tyre makers and automotive parts makers (hoses, seals, belts, gaskets) - glove makers (NBR latex) - adhesive tape and label makers (C5 resins) - polarizer and LCD panel makers (retardation films) - camera-lens module makers - pharmaceutical container and syringe makers - semiconductor fabs and wafer-carrier makers - lithium-ion cell makers (EV, ESS, consumer) - printer/toner OEMs - fragrance houses

Revenue$2.8B
Employees4,425
Market CapN/A
Founded1950
Tokyo, Japan
YPF

YPF Sociedad Anonima

Premium
Information Technology

YPF is Argentina's largest integrated energy company and its national champion in hydrocarbons. Per the company's FY2025 annual-report press release, it produces roughly 32% of Argentina's crude oil and 27% of its natural gas, and supplies about 55.5% of the domestic fuels market through more than 1,600 service stations; management cited a 59% fuel market share in 2Q26. Since late 2023, under Chairman and CEO Horacio Marín, YPF has executed the "4x4 Plan," a deliberate pivot from a sprawling conventional-asset base towards a focused Vaca Muerta shale producer with export ambitions. It has divested most mature conventional fields, sold non-core holdings (Profertil, MetroGAS, Manantiales Behr), consolidated high-quality shale acreage, and is sponsoring transformational export infrastructure — the Vaca Muerta Oil Sur (VMOS) pipeline and the Argentina LNG project with Eni and ADNOC's XRG. In 2Q26 it delivered record adjusted EBITDA of USD 2.8bn at a 43% margin, with net leverage at an 11-year low of 1.09x. --- ### Company's own description YPF describes itself (FY2025 annual-report release, 26 March 2026) as the largest energy company in Argentina and one of the largest shale operators outside the United States, with an integrated offering spanning fuels, natural gas, electricity, petrochemicals, lubricants and agricultural products. SEC-filing summaries describe operations across the full value chain: exploration and production of crude oil and natural gas; refining and petrochemicals; transportation and storage; marketing and retail of fuels and lubricants; gas commercialisation and power generation; LNG; fertilisers (until the December 2025 Profertil exit); and renewable energy. ### Independent characterisation YPF is best understood today as a shale-oil growth company wrapped inside a dominant domestic downstream franchise, with a state controlling shareholder. Three economic engines drive value: 1. **Upstream (Vaca Muerta shale oil):** The growth and value engine. Shale oil output averaged 165 kbbl/d in 2025 (+35% y/y), 205 kbbl/d in 1Q26 and 213 kbbl/d in 2Q26 (+47% y/y), now about 80% of YPF's oil output. Shale-hub lifting cost was USD 4.0/boe in 1Q26 (1Q26 6-K). Conventional oil fell to ~66 kbbl/d in 1Q26 (–45% y/y) as divestments progressed. 2. **Midstream & Downstream (refining and marketing):** A quasi-utility-scale franchise of three owned refineries plus Refinor (100% since October 2025), processing a record 351 kbbl/d in 2Q26, with integrated R&M adjusted EBITDA of roughly USD 23–30/bbl in 2Q26 depending on the inventory-effect treatment. This segment monetises shale crude domestically at import-parity-linked prices following the deregulation of fuel pricing under the Milei administration. 3. **Gas, LNG & New Energies:** Natural gas production (36.2 Mm3/d in 2025), gas marketing, a stake in YPF Luz (power), and the long-dated Argentina LNG export option (12 mtpa with Eni/XRG; FID targeted for end-2026). ### Revenue model YPF is overwhelmingly a product-sales business (commodities and refined products). There is no meaningful subscription or licensing revenue. Indicative mix (1Q26 segment revenue disclosure, 6-K): diesel USD 1,745M and gasolines USD 1,131M (Midstream & Downstream), natural gas USD 463M across segments, plus crude oil, jet fuel, LPG, petrochemicals, lubricants and other products. Services revenue (e.g., station services, YPF Luz power sales accounted under equity method) is immaterial at group level. ### Value-chain position and customers **Upstream:** operator of the majority of its shale blocks (Loma Campana with Chevron, La Amarga Chica, Bandurria Sur, La Angostura Sur, Bajo del Toro/Bajo del Toro Norte, Rincón La Ceniza/La Escalonada, Aguada Villanueva, Las Tacanas, Meseta Buena Esperanza). **Customers:** retail motorists (service-station network), commercial fleets and transport companies, agribusiness (YPF Agro), airlines (jet fuel), industrial users, power generators, CAMMESA (wholesale power), gas distributors, and export buyers (crude to Chile via the Trasandino pipeline; seaborne crude exports; prospective LNG offtakers). **End-markets:** Argentine transportation fuels, agriculture, industry, residential gas, power generation, petrochemicals, and — increasingly — international crude and (from ~2031) LNG.

Revenue$18.4B
EmployeesN/A
Market Cap$21.8B
Founded1922
Ciudad Autónoma de Buenos Aires, Argentina
Yankuang

Yankuang Energy Group Company Limited

Premium
Information Technology

Yankuang Energy is one of China's largest listed coal producers and the main listed platform of Shandong Energy Group, a top-tier provincial state-owned energy conglomerate. It produced a record 182.4 Mt of saleable coal in FY2025 across five production bases: Shandong, Shaanxi–Inner Mongolia, Xinjiang, Australia (through Yancoal Australia) and the newly consolidated Xibei Mining. It also runs an integrated coal-chemicals business with about 9.8 Mt of annual output, spanning methanol, acetic acid, ethylene glycol, caprolactam, polyformaldehyde, urea and coal-to-liquids. Further businesses include mining equipment, smart logistics and in-group finance. Its strategy is shifting from "coal + chemicals" toward a "coal + chemicals + power/new energy" model. The RMB 16.4bn acquisition of Shandong Energy's power and renewables platform in 2026 is the centrepiece, adding roughly 12–13 GW of capacity. The investment case rests on low-cost scale, international diversification, high payouts (a ~50% payout policy for 2026–2028) and coal-price leverage. These are offset by heavy related-party dependence, leverage and long-run decarbonisation risk. --- ### Company's own description Recent corporate releases describe Yankuang as a large international energy company. It lists its businesses as mining, high-end chemicals and new materials, new energy, high-end equipment manufacturing, and smart logistics (Yankuang 2022 annual results release, 27 Mar 2023). The FY2025 annual report describes ongoing work under the group's 15th Five-Year Plan. That plan focuses on high-end chemicals, smart logistics and new-energy integration, with the stated aim of becoming a world-class clean energy company (FY2025 annual report summary via sustainabilityreports.com). The FY2025 ESG report frames the 2026 objective as continued optimisation of a "coal + chemicals + new energy" portfolio (FY2025 ESG report coverage, 27 Mar 2026). ### Independent characterisation Economically, Yankuang is a commodity producer with partial downstream integration: **Coal (dominant profit engine):** About 66% of FY2025 IFRS revenue (RMB 88.7bn of RMB 133.3bn) and the bulk of gross profit. The company sells thermal coal, semi-soft coking/PCI coal and washed coal to Chinese power utilities, steelmakers, chemical producers and seaborne customers in Japan, Korea, Taiwan and Southeast Asia through Yancoal Australia. Revenue is driven by volume times realised price; costs are largely fixed and mine-level. **Coal chemicals:** About 18% of FY2025 revenue (RMB 24.3bn). This is a captive offtake channel that converts self-produced coal into methanol, acetic acid, ethylene glycol, caprolactam, POM, urea and Fischer–Tropsch liquids. It provides partial counter-cyclicality: chemicals margins often widen when coal (the feedstock) is cheap. Q1 2026 bore this out, when chemicals profit reached a four-year high while coal prices were weak (Q1 2026 results coverage). **Power and heat:** Historically small (RMB 2.3bn FY2025 revenue). Post-2026 acquisition it becomes a material third pillar, with about 12–13 GW of thermal, wind, solar and storage capacity plus a nationwide electricity retail licence. **Mining equipment, non-coal trade and logistics, finance:** These support businesses serve both the group and third parties. The Wubo Technology smart-logistics subsidiary is proposed for a separate HKEX listing. **Revenue model mix.** Almost entirely product sales (coal, chemicals, electricity). There is a small service and financial component (logistics services, finance-company interest and leasing income). There is no meaningful subscription or licensing revenue. **Value chain position.** Upstream resource owner and miner, with mid-stream processing (washing, chemicals, power) and logistics (rail and port handling via Wubo and the group network). Yankuang is a price-taker on coal; pricing follows China domestic benchmarks (e.g., Qinhuangdao 5,500 kcal thermal) and seaborne indices (Newcastle) for Australian output. **Customer types and end-markets.** Thermal power generators (largest), steel/coke producers, chemical and fertiliser manufacturers, building materials, and seaborne Asian utilities and steelmakers. Post-acquisition, it also serves retail electricity customers.

RevenueN/A
Employees77,957
Market CapN/A
Founded1997
Shandong Province, China
WELLS

WELLS PERFORMANCE MATERIALS LIMITED

Premium
Information Technology

| Field | Detail | |---|---| | Entity profiled | Wells Performance Materials Limited (formerly Wells Plastics Limited) | | Match rationale | Exact legal-name match to "Wells Plastics Limited" for the period 7 Jun 1984 – 7 Jun 2024; same company number, still active [S10] | | Current legal name | WELLS PERFORMANCE MATERIALS LIMITED [S10] | | Former name(s) | WELLS PLASTICS LIMITED (7 Jun 1984 – 7 Jun 2024) [S10] | | Trading names | Wells PM; Wells Performance Materials; brands BACTIglas™, Reverte™, Compol™ [S59] | | Company number | 01822612 (England & Wales) [S10] | | Legal form | Private limited company [S10] | | Listing status | Not listed. Privately held. The input list's "Public company" classification is incorrect. | | Founded / incorporated | Incorporated 7 June 1984 [S10]; founded in 1984 by Danny Wells [S59] | | Jurisdiction | England & Wales (Companies Act) | | Registered office / HQ | Emerald Way, Stone Business Park, Stone, Staffordshire, ST15 0SR, United Kingdom [S10][S59] | | SIC code | 22290 – Manufacture of other plastic products [S10] | | Stock exchange / ticker | None (not listed) | | ISIN / CUSIP | Not applicable (no listed securities) | | Fiscal year end | 30 June [S10][S19] | | Latest filed accounts | Full accounts for the year to 30 June 2025, filed 14 April 2026 (35 pages) [S19] | | Next accounts due | Year to 30 June 2026, due by 31 March 2027 [S39] | | Latest confirmation statement | Made 16 September 2026 "with updates" [S19] | | Immediate parent / PSC | Wellstopco Limited (company no. 14248252), holding ≥75% of shares and voting rights, notified 26 March 2026 [S61] | | Prior PSC | R&E Holdings Ltd (company no. 03356524), from 22 Sep 2022 to 26 Mar 2026 [S61] | | Ultimate controlling party | Not publicly disclosed in sources retrieved. Per the 2022 MBO announcements, it is management-owned (Carl Birch, Stuart Law and Dr Gary Ogden) [S52] | | Employees (latest) | "Nearly 60" (WMG case study, 29 June 2026) [S24]; 60 (PitchBook) [S62]; 57 (Datanyze) [S63] | | Auditor | Not publicly disclosed in sources retrieved. It is named in the filed full accounts. | | Market capitalisation | Not applicable (private). Equity value not publicly disclosed. | | Website | https://wellspm.com (legacy: wellsplastics.com) [S59][S57] | | Brand websites | bactiglas.com; revertebio.com (launched March 2025); reverteplastics.com (legacy) [S59][S60] | | Stated capacity | In excess of 12,000 tonnes per annum (current) [S4]. It was over 10,000 t/a at the time of the October 2022 MBO [S52][S53]. | | Operations | 24/7 manufacturing across four sites in Stone, covering innovation, manufacturing and warehousing [S4] | | Metric | 2013 | 2022 | 2024 | 2026 | |---|---|---|---|---| | Employees (headcount, approx.) | 40 | — | — | 60 | *Sources: "over 40" at the Stone site (British Plastics, c. Jan 2013) [S3]; "nearly 60" (WMG, June 2026) [S24]. One aggregator (a-leads) shows only 25 LinkedIn-linked employees with −7.4% yearly growth [S7]. This reflects LinkedIn coverage rather than true headcount and conflicts with the 57–60 range from other sources.* Wells Performance Materials is a family-founded, now management-owned specialty chemicals manufacturer in Stone, Staffordshire. It describes itself as the largest independent specialist additive masterbatch and compound producer in the United Kingdom. Wells does not make colour masterbatch. Instead, it formulates and compounds functional additives into easy-to-dose carrier pellets for plastics processors and brand owners. These additives include antimicrobials, oxo-biodegradation promoters, slip and antiblock agents, antistatics, UV stabilisers, antioxidants, flame retardants, blowing agents, fragrances, processing aids and purge compounds. Its two proprietary brands, BACTIglas™ (antimicrobial) and Reverte™ (biodegradable additive for polyolefins), give it intellectual property and regulatory know-how unusual for a firm of roughly 60 people. Around these brands sits a toll-compounding and bespoke-formulation business with over 12,000 t/a of capacity. Wells sells into film, packaging, agriculture, automotive, medical and food-contact markets in the UK, Europe and export territories. Its competitive edge rests on handling difficult raw materials, rapid development and regulatory expertise. Its principal exposure is to plastics-policy risk, especially around oxo-degradable additives and PFAS. --- ### What the company does Wells is an additive masterbatcher and compounder. A masterbatch is a concentrated blend of one or more additives dispersed in a polymer carrier, supplied as pellets. A processor (a film blower, injection moulder or fibre spinner) adds it at a low let-down ratio to base resin to give the finished article a functional property. Many functional additives are powders, liquids, waxes or high-viscosity fluids that are difficult, hazardous or inconsistent to dose directly. Wells' core value proposition is converting these into homogeneous, free-flowing pellets so the customer gets the function without the handling problem [S4][S59]. The company's own description, paraphrased from its website and trade-directory listing, positions it as follows [S4][S59]: - the UK's largest independent specialist additive masterbatch and compound manufacturer, with over 12,000 t/a of capacity; - working across a wide range of polymer bases, including polyolefins, biopolymers, bio-based and compostable polymers, EVAs, EMAs and nylons; - offering pellet formats from conventional strand pellets through die-face-cut to micro-pellets; - providing the full chain from product development, pilot trials and material selection to full-scale production, plus a catalogue of off-the-shelf grades; - developing, manufacturing and owning the BACTIglas™ and Reverte™ brands. The Sales & Marketing Director has emphasised that, although Wells performs R&D both internally and for clients, it sees itself as a manufacturer whose goal is commercially viable solutions [S23]. ### Business model and revenue model | Revenue stream | Description | Disclosure status | |---|---|---| | Proprietary branded additives | BACTIglas™ antimicrobial masterbatches, compounds and powders; Reverte™ biodegradable masterbatches | Revenue split not publicly disclosed | | Catalogue functional masterbatches | Slip, antiblock, antistatic, UV, antioxidant, flame retardant, blowing agents, fragrance, processing aids, purge compounds | Not disclosed | | Bespoke formulations | Customer-specific additive packages developed and manufactured by Wells | Not disclosed | | Contract / toll compounding | Manufacturing to customers' own formulations on Wells' twin-screw lines | Not disclosed | | Technical services | Development, pilot trials, testing (expanded with a new Instron testing system in 2026) [S24] | Not disclosed; likely embedded in product pricing | | Biopolymer compounds | Compol™ bio-based and biopolymer materials | Not disclosed | **Independent characterisation:** Revenue is overwhelmingly product revenue (tonnes sold × price per kg), with no material subscription or licensing component in public sources. Branded ranges are sold via direct sales and, since 2012, an expanded international distributor network [S59]. Pricing is likely cost-plus on raw-material indices with a premium for proprietary chemistries, although no pricing disclosures exist. ### Value-chain position | Stage | Players | Wells' role | |---|---|---| | Upstream | Polymer producers (resins); additive chemical producers (slip amides, antistatic GMS, HALS UV stabilisers, silver/zinc antimicrobials, transition-metal pro-oxidants, etc.) | Buyer of carrier resins and raw additives | | Mid-stream | Masterbatch and compound producers | Wells' core position | | Downstream conversion | Film blowers, sheet extruders, injection moulders, fibre spinners | Primary direct customers | | End-use | Retailers, brand owners, packaging buyers, medical-device OEMs, agriculture | Often specify Wells' brands (e.g. antimicrobial refuse sacks, biodegradable carrier bags) | Wells sits in the mid-stream of the plastics value chain: ### Customer types and end-markets | End-market | Representative applications | Key brand / product | |---|---|---| | Flexible packaging & film | Slip/antiblock for PE film, antistatic film, stretch and shrink film | Slips, Antiblocks, Antistatics, Processing Aids | | Retail/carrier bags & refuse sacks | Biodegradable bags, antibacterial refuse sacks | Reverte™, BACTIglas™ | | Agriculture | UV-stabilised films, biodegradable mulch-type applications | UV masterbatches, Reverte™ | | Medical devices | Antimicrobial polymer components | BACTIglas™ | | Food contact / food packaging | Antimicrobial packaging, slip/antiblock | BACTIglas™, Slips | | Automotive | Flame retardants, stabilisers, bespoke compounds | Flame Retardants, Antioxidants | | Mass transport | Antimicrobial touch surfaces | BACTIglas™ | | Point-of-sale / consumer goods | Scented articles, odour masking in recyclate | Fragrances | | Foams / lightweighting | Endothermic and exothermic chemical foaming | Blowing agents | | Recycling | Odour elimination and stabilisation of recyclate | Fragrances, Antioxidants | The company lists end customers in automotive, medical, food, and agriculture [S59], plus food packaging [S24]. Historic investor descriptions add consumer, construction and agriculture [S8][S57]. BACTIglas™ is positioned for medical devices, mass transport and food packaging [S59], with documented use in refuse sacks [S63]. Reverte™ historically had particular success in plastic carrier bags [S51]. Wells also states that it serves customers ranging from polymer producers to medical-device makers [S59].

RevenueN/A
Employees60
Market CapN/A
Founded1984
Staffordshire, United Kingdom
Waste

Waste Management Inc.

Premium
Information Technology

WM is North America's largest integrated environmental-services company. It controls the continent's largest landfill network and collection fleet. It is the largest post-consumer recycler and a leading producer of renewable natural gas (RNG) from landfill gas. It runs the industry's largest heavy-duty natural-gas truck fleet, at more than 12,000 trucks [S1]. The core franchise is a vertically integrated collection-transfer-disposal network with high internalization, at 73.0% of disposal costs in Q2 FY2026 [S2]. That network generated a 38.6% adjusted segment EBITDA margin in Q2 FY2026 and supports durable pricing power, with core price of 5.7% in Q2 FY2026 [S2]. Since 2024, WM has added a regulated medical-waste and secure-shredding platform through the $7.2B Stericycle acquisition [S9]. It has also nearly completed a roughly $3B multi-year build-out of recycling automation and RNG plants. Management expects those projects to lift combined sustainability EBITDA toward $1B in 2027 [S1]. The 2026 equity story is "harvest mode." Capex is falling, free cash flow is guided up about 29% to $3.75–3.85B, and about $3.5B is planned for shareholder returns [S1]. Leadership passes from Jim Fish to John Morris in January 2027 [S6]. --- **Company self-description (paraphrased from the FY2025 proxy and 10-K language) [S4].** Waste Management, Inc. describes itself as a holding company whose operations are all conducted through subsidiaries. Those subsidiaries are managed locally within distinct geographic markets. - WM positions itself as North America's leading provider of comprehensive environmental solutions across the U.S. and Canada. - It partners with customers and communities to manage and reduce waste at each stage from collection to disposal. - It recovers materials and produces renewable energy along the way. - Since the 2024 Stericycle acquisition, its Healthcare Solutions segment provides regulated waste, compliance and secure information destruction services in the U.S., Canada and Western Europe. **Independent characterization.** WM is best understood as an infrastructure-like, route-density business layered on top of a scarce-asset disposal monopoly. **Collection:** Collection generates about 61% of net revenue (FY2025: $15.42B of $25.20B) [S1]. Pricing is driven by contracts and subscriptions. **Disposal:** Landfills and transfer stations generate about 21% of net revenue (FY2025: $5.28B) [S1]. **Strategic moat:** The landfill and transfer network is the real moat. New landfill permits are scarce and slow, so owners of permitted airspace capture tipping-fee economics and internalize their own collected volumes. This drives superior margins versus collection-only competitors. **Recycling and Renewable Energy:** These are commodity-exposed businesses that are being "de-risked." Automation lowers processing cost per ton, and fees and offtake contracts reduce price exposure. Even so, single-stream commodity prices ($65–75/ton in H1 FY2026) and RIN prices ($2.32–2.33) remain swing factors [S2][S3]. **Healthcare Solutions:** The former Stericycle business is a route-based specialty-services adjacency. It covers regulated medical waste, pharmaceutical and hazardous waste, and Shred-it-type secure information destruction (SID). It is margin-dilutive today, at a 16.9% adjusted EBITDA margin in FY2025 [S1], but is being integrated into WM's field structure. **Revenue model mix (FY2025 net operating revenue) [S1]** Characterization of the mix: **Service and subscription:** About 92% of revenue comes from contracted, recurring or tonnage-based services. **Product-like:** About 8% is commodity or energy revenue from recycled materials, RNG and RINs. **Licensing:** Licensing revenue is immaterial or nil. **Value-chain position.** WM spans the whole post-consumer value chain: 1. Generation-point services: containers, compactors and Bagster. 2. Collection logistics. 3. Transfer and consolidation. 4. Processing: material recovery facilities (MRFs), organics and medical-waste treatment through autoclave and incineration. 5. Final disposal: landfill. 6. Energy and material monetization: landfill-gas-to-electricity, RNG and sale of recycled commodities. **Customer types and end-markets.** **Customers:** Residential households (subscription and municipal contract), commercial businesses, industrial and construction sites, municipalities, national accounts, healthcare providers (hospitals, clinics, physician and dental offices, pharmacies) and document-sensitive enterprises for SID [S1][S4]. **End-markets:** Housing and construction activity drives roll-off volumes. Retail, hospitality and office activity drive commercial volumes. Industrial production drives special waste. Healthcare utilization drives regulated medical waste. Packaging and paper markets drive recycled-commodity demand. Transportation fuel markets drive RNG demand under the Renewable Fuel Standard and low-carbon fuel standards.

Revenue$25.2B
EmployeesN/A
Market CapN/A
Founded1968
Texas, US
VivimedLabs

Vivimed Labs Ltd

Premium
Information Technology

### Identity table | Field | Detail | Source | |---|---|---| | Legal name | Vivimed Labs Limited | Exchange filings 2026 | | Former names | Emgi Pharmaceuticals & Chemicals Pvt Ltd (incorporated 22 Sep 1988); converted to public company and renamed Emgi Pharmaceuticals & Chemicals Ltd (21 Apr 1994); renamed Vivimed Labs Limited (22 Apr 1997) | Company background (Arihant Capital company profile) | | Founding / incorporation | 22 September 1988 (some aggregators cite 1991 as founding; the statutory incorporation date is 1988) | MCA/CIN; aggregator profiles conflict | | CIN | L02411KA1988PLC009465 | Form G (June 2026) | | PAN | AAACV6060A | Form G (June 2026) | | Incorporation jurisdiction | Karnataka, India (Registrar of Companies, Bangalore) | MCA records | | Registered office | Plot No. 78-A, Kolhar Industrial Area, Bidar, Karnataka – 585403, India | Form G (June 2026) | | Corporate office | 3rd Floor, 6-3-866/1/G1, Greenlands, Begumpet, Hyderabad, Telangana – 500016, India (per company letterhead on exchange filings) | NSE disclosure 13 Feb 2026 | | Stock exchanges / tickers | BSE: 532660; NSE: VIVIMEDLAB (currently traded in "BE" series, trade-for-trade settlement); also referenced by Metropolitan Stock Exchange (MSE) | NSE circular 10 Dec 2025; MSE circular 17 Dec 2025 | | ISIN | INE526G01021 | NSE circular | | LEI | 335800LYN9TN3F87WV86 | Financialfilings.com index | | CUSIP | Not applicable (no US listing) | — | | Face value | INR 2 per share (historically INR 10) | NSE circular 10 Dec 2025 | | Shares outstanding | ~82.93 million (FY2026) | S&P Global via StockAnalysis | | Fiscal year end | 31 March | Filings | | Employees (latest) | 552 (per Form G, June 2026); 586 cited by PitchBook | Form G; PitchBook | | Employee trend (3-year) | Not publicly disclosed in verified form | — | | Statutory auditor | SVRL & Co., Chartered Accountants (qualified opinions on FY2025 and FY2026) | FY2026 results coverage; FY2025 auditor report | | Market capitalisation (current) | ~INR 54.7 crore (INR 547 million) at INR 6.59 close on 7 Oct 2026 × 82.93M shares (analyst calculation) | StockAnalysis price; share count | | Insolvency status | CIRP admitted 15 Apr 2026, CP(IB) No. 91/BB/2025, NCLT Bengaluru; IRP T. Narayana Swamy (Reg. IBBI/IPA-002/IP-N01078/2020-2021/13427) | NCLT order; exchange filings | | Website | https://www.vivimedlabs.com | Form G | Vivimed Labs is a Hyderabad-managed, Bidar-registered Indian pharmaceutical manufacturer that once operated as a globally diversified specialty chemicals and API group, with subsidiaries in the UK (James Robinson), Spain and Mexico (UQUIFA), Hungary (Soneas), and the US. Over the last decade it has progressively dismantled that portfolio: selling specialty chemical product lines to Clariant (2015), exiting its US generics joint venture to Strides (2019), and ceasing to consolidate its European API arm around FY2022. What remains is a sub-scale domestic finished-dosage and API manufacturer with five plants across Telangana, Uttarakhand and Karnataka, revenue from operations of INR 699.9 million in FY2026 (down from INR 8.6 billion consolidated in FY2021), negative net worth, defaulted bank debt assigned to an asset reconstruction company, a pending CBI bank-fraud investigation (stayed by the Telangana High Court), and an active CIRP. The equity is effectively an option on a resolution outcome. --- ### What the company does today On the basis of its most recent statutory and insolvency disclosures, Vivimed Labs is today primarily a manufacturer of pharmaceutical dosage forms and active pharmaceutical ingredients (APIs). The IRP's Form G (14 June 2026) describes the corporate debtor as operating in the business of manufacturing pharma dosage forms at Hyderabad, Haridwar, Kashipur and Bidar. Aggregator and exchange descriptions characterise the company as engaged in APIs, contract development and manufacturing (CDMO), finished dosage formulations (FDF), specialty chemicals and retail branded formulations. ### The company's own description Vivimed's legacy self-description (2019 investor presentations) framed the group around three pillars — "Leveraging Global Presence," "Partnering Innovation," and "Delivering Affordable Chemistry" — and around two businesses: (i) a pharmaceuticals business anchored by UQUIFA (API and CDMO, with Spain, Mexico, Hungary and India operations, USFDA-approved sites) plus Indian FDF; and (ii) a specialty chemicals business (hair dyes, photochromic dyes, anti-microbials, imaging chemicals), which in 2019 the company itself labelled as "under divestment." A more recent company description (repeated by brokers) states that Vivimed manufactures APIs, intermediates and nutraceutical ingredients with an export orientation, and supports innovator pharma companies through custom synthesis from gram scale for clinical trials through launch and life-cycle management. That description appears to reflect the UQUIFA-era CDMO franchise and is likely outdated relative to the current asset base. ### Independent characterisation Our independent characterisation is that Vivimed is now a distressed, sub-scale Indian contract and own-brand formulations manufacturer whose revenue has fallen roughly 92% in five years (consolidated revenue from operations from ~INR 8,615 million in FY2021 to INR 699.9 million in FY2026). Its business model is predominantly product sales (manufactured formulations and APIs, including likely loan-licence and third-party manufacturing), with no meaningful subscription, licensing or service income disclosed. Its historic value-chain position spanned the middle of the pharma chain — API/intermediate synthesis and finished dosage manufacturing — selling to generic drug companies, innovators (CDMO) and distributors in India and export markets. Today, with working capital starved (inventory fell from INR 2,408 million in FY2022 to INR 127 million in FY2026), the plants are almost certainly operating far below installed capacity. ### Revenue model mix | Revenue type | Historic (to FY2021) | Current (FY2026) | Comment | |---|---|---|---| | Product sales — APIs / intermediates | Major (via UQUIFA) | Minor/unclear | UQUIFA no longer consolidated (see §3, §11) | | Product sales — finished dosage forms | Meaningful | Dominant | Form G describes the business as dosage-form manufacturing | | CDMO / custom synthesis services | Meaningful (UQUIFA, Soneas) | — | Likely negligible post-deconsolidation | | Specialty chemicals | Dominant pre-2015; "under divestment" by 2019 | — | Residual activity, if any, undisclosed | | Licensing / royalties | Not disclosed | Not disclosed | — | | Other revenue | — | INR 63.19 million (FY2026) | S&P classification "other revenue" | ### Customer types and end-markets Customer types historically included global generic pharmaceutical companies (API buyers), innovator pharmaceutical companies (CDMO), personal-care and cosmetics majors (hair dyes, anti-microbials), ophthalmic lens makers (photochromic dyes), Indian pharma marketers (contract formulation), and government/export registrations (e.g., Uzbekistan product approvals in 2021). Current customer concentration is not disclosed.

Revenue$0.0B
Employees552
Market CapN/A
Founded1988
Karnataka, India
Victrex

Victrex plc

Premium
Information Technology

Victrex is the global pioneer and volume leader in polyether ether ketone (PEEK). PEEK is a semi-crystalline, ultra-high-performance thermoplastic that combines mechanical strength, high-temperature capability, and chemical, wear and fatigue resistance. The company says it holds more than 45% of global PEEK volume, over twice its nearest rival (CMD, 24 Sep 2026). Its vertically integrated, predominantly UK-based chain runs from monomer manufacture in Rotherham to polymerisation at Hillhouse, with additional capacity in Panjin, China. Through Invibio it also serves implantable and non-implantable medical devices. The group sells polymer, film, compounds and selected semi-finished forms into Aerospace & Defence, Automotive, Electronics, Energy & Industrial, Value Added Resellers and Medical. After a profit downturn from FY2023 to FY2025 driven by mix, pricing, FX and a troubled China plant, a new CEO launched a self-help turnaround. The plan targets roughly 50% gross margin and a mid-20s operating margin by FY2031, and resets capital returns around buybacks. --- ### What the company does Victrex manufactures and sells polyaryletherketone (PAEK) polymers, principally PEEK, under the VICTREX™ brand, plus medical-grade PEEK under the PEEK-OPTIMA™ brand via its Invibio subsidiary. Customers use the polymer to replace metals, fluoropolymers and lower-grade plastics in demanding applications. Typical examples are aircraft brackets and clips, automotive transmission and braking components, semiconductor chemical-mechanical planarisation (CMP) retaining rings, smartphone acoustic film, subsea and oilfield seals and pipes, food-processing equipment, spinal fusion cages, cranio-maxillofacial plates and cardiac pump components. ### Company's own description (paraphrased from FY2025 Annual Report and 2026 RNSs) In its FY2025 reports, Victrex describes itself as an innovative world leader in high-performance polymer solutions. It cites more than 40 years' experience in PEEK and PAEK-based polymers, semi-finished and finished parts, and positions its products as enabling environmental and societal benefits. In September 2026 the corporate website was re-badged around a broader proposition: a leading global materials and engineered-solutions partner that transforms performance in systems the world relies on. The CMD release added "Aerospace and Defence" to the end-market list and dropped the "sustainable materials" framing in favour of mission-critical, certified applications. ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue model | Overwhelmingly product sales: polymer granules and powders, film, compounds and some semi-finished parts. Medical includes some application-development support, but licensing and service revenue is not separately disclosed and is understood to be immaterial. No subscription revenue. | | Pricing basis | Per-kilogram pricing. Group average selling price was £70.3/kg in FY2025 (FY2024 £78.0/kg; FY2023 £85.3/kg). Medical carries far higher prices per kg than industrial grades. | | Contracting | Annual contracts with major VARs typically renew at the start of the calendar year. Long-duration specification positions apply in aerospace, auto and medical (qualification cycles of several years). | | Value-chain position | Upstream and midstream. Vertically integrated from monomer (BDF, made in-house at Rotherham) through polymerisation (Hillhouse UK; Panjin China). Sells mostly to compounders, stock-shape VARs, moulders, Tier-1s and OEM device makers rather than end consumers. | | Customer types | VARs (stock shapes and compounds; among the largest customers; lowest cost-to-serve); Tier-1 and Tier-2 automotive suppliers; aerospace OEM supply chains; semiconductor equipment and consumer-electronics component makers; oil & gas service companies such as TechnipFMC; medical device OEMs. | | Division split FY2025 | Sustainable Solutions £233.9m (79.9%); Medical £58.8m (20.1%) | | End-market volume split FY2025 | VARs 1,797t (43%); Transport (Aero + Auto) 1,012t (24%); Energy & Industrial 705t (17%); Electronics 464t (11%); Medical 186t (4%) — FY2025 Prelims | ### Independent characterisation Victrex is a niche, high-barrier specialty chemicals business whose economics depend heavily on mix. Medical generates about 20% of revenue on under 5% of volume, at gross margins of 75–80%. Sustainable Solutions runs at roughly 34–38% gross margin. The FY2023–FY2025 margin compression (group gross margin from 53.0% to 45.3%) came less from lost volume than from four factors: 1. Rapid growth in low-touch, lower-price VAR and Energy & Industrial tonnage, which pulled ASP down 18% over two years. 2. A structural share shift in US spine from PEEK to porous and expandable titanium cages, plus volume-based procurement (VBP) price resets in Chinese spine. 3. Sterling strength, worth about £8m of PBT headwind in FY2025. 4. Losses at the Panjin plant (about £8m operating loss in FY2025), which never reached its 1,500t nameplate and was impaired by £60.6m in H1 FY2026. The investment case under the new CEO rests on restoring gross margin through cost and mix discipline, not on volume, which has recovered strongly.

Revenue$0.4B
Employees1,000
Market CapN/A
Founded1993
Thornton Cleveleys, United Kingdom
Vestaron

Vestaron Corporation

Premium
Information Technology

Vestaron Corporation was an early commercial pioneer of peptide-based bioinsecticides. These are crop protection products built from insecticidal peptides that originally came from spider venom, optimised by the company and produced through microbial (yeast) fermentation. Its lead active, the SPEAR® peptide, received a new Insecticide Resistance Action Committee mode-of-action classification (IRAC Group 32). That classification places the active at the nicotinic acetylcholine receptor but at a different binding site from neonicotinoids and spinosyns. Vestaron positioned its products as matching the efficacy of conventional synthetics while offering a biological's safety profile: a 4-hour re-entry interval, a 0-day pre-harvest interval, MRL exemption, and low toxicity to pollinators and beneficial insects. After launching SPEAR products in the U.S. from 2018–2020, the company expanded into Canada, Mexico and EU emergency-use markets, and registered a second active, BASIN™, in 2024. In May 2026 Suterra acquired its product and R&D assets, which effectively ended Vestaron's life as an independent commercial operator. --- ### What the company does Vestaron discovered, optimised, registered and commercialised peptide insecticides. Peptides are short chains of amino acids, smaller than proteins. Its proprietary process starts with natural insecticidal peptides found in spider venom and other venomous animals, then modifies them. Production runs through fermentation (Techleap/citybiz profile, March 2025; Packer, June 2026). The company's long-standing thesis is the following: - Six key muscle and nerve receptors account for about 80% of the global insecticide market. Vestaron said in 2022 that it had peptides in its pipeline suited to all six (Global AgInvesting, May 2022). - The nicotinic acetylcholine receptor, which SPEAR targets, accounts for about 30% of the roughly USD 18 billion global insecticide market (company-cited figure, repeated across 2019–2022 releases). - Peptides can hit validated neuromuscular targets at new binding sites. This avoids cross-resistance with incumbent chemistries while keeping a biological's residue and safety profile. ### Company's own description Recent boilerplate describes Vestaron as leading a global revolution in crop protection by creating novel, effective and sustainable solutions for growers facing the challenges of modern agriculture. It also notes that Vestaron was the first agriculture and food company inducted into the Global CleanTech 100 Hall of Fame (GlobeNewswire, July 2025). Earlier boilerplate (2019) called Vestaron "The Peptide Company." It described the mission as improving the safety, efficacy and sustainability of crop protection by migrating from chemical pesticides to biological peptides (MEDC, April 2019). Vestaron has no annual report because it is private, so this description is taken from press boilerplate. ### Business model and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Revenue type | Almost entirely product sales of formulated end-use insecticides. No subscription revenue. Licensing/royalty revenue not disclosed | Preqin describes a direct-sales model around SPEAR and BASIN | | Pricing | SPEAR LEP priced at parity with conventional synthetic chemistries | IBMA interview (2025) | | Route to market | Own territory managers plus regional distribution partners (e.g., Wilbur-Ellis in the U.S.; Oxygen AgroShield in Greece; Premier Shukuroglou in Cyprus; Lainco in Iberia) | Vegetable Growers News (Nov 2021); Farm Progress; GlobeNewswire (2024–2025) | | Manufacturing | Outsourced fermentation: first Capua BioServices (Italy), then a long-term agreement with ADM from October 2024 | AgriBusiness Global; GlobeNewswire (15 Oct 2024) | | Product/service mix | Product ~100%; service revenue n/d | Analyst characterisation | ### Value-chain position Vestaron sat at the active-ingredient discovery and branded end-product layer of the crop protection value chain. It was asset-light in manufacturing, relying on contract fermentation, and channel-dependent in distribution. It sold through agricultural retail and distributors to growers. It did not own retail or large-scale manufacturing. ### Customer types and end-markets | End-market | Crops / pests | Products | |---|---|---| | Specialty field crops (core) | Tree nuts (pistachio, almond: navel orangeworm), grapes, stone fruit, vegetables (crucifers, tomato, pepper), apples (codling moth) | SPEAR LEP, BASIN FLEX, LEPROTEC | | Protected agriculture / greenhouses | Thrips, whiteflies, aphids, mites | SPEAR T | | Broad-acre row crops | Cotton (bollworm), soybean (looper), rice, armyworms | SPEAR RC | | EU emergency-use markets | Tomato (Tuta absoluta), olive (Prays oleae) | SPEAR LEP under Article 53 EUAs | | Organic production | Bt-based caterpillar control | LEPROTEC (OMRI listed) | Early-stage plans (c.2012) also targeted animal health, public health and lawn & garden, then sized by the company at a combined USD 15.4 billion (Xconomy). No commercial activity in these non-crop markets has been publicly documented. ### Independent characterisation Vestaron was a technically successful but commercially sub-scale biological insecticide innovator. It achieved the hardest milestones in the category: novel IRAC classification, EPA registration of two new active ingredients, multi-country approvals, a cumulative footprint above one million treated acres, and blue-chip strategic investors. However, it never reached disclosed profitability or the scale needed to fund global registration (EU approval was still pending, targeted for 2027) on its own. The May 2026 sale to a vertically integrated strategic buyer is the classic end-game for venture-funded ag-input innovators. Its IP becomes a portfolio extension for a player with manufacturing scale and global registrations.

RevenueN/A
Employees25
Market Cap$0.4B
Founded2005
MI, US
UPM-Kymmene

UPM-Kymmene Oyj

Premium
Information Technology

| Item | Detail | |---|---| | Legal name | UPM-Kymmene Oyj (UPM-Kymmene Corporation) | | Trading / brand name | UPM | | Former names / predecessors | Kymmene Corporation (Kymmene Oy) and Repola Oy, which owned Yhtyneet Paperitehtaat Oy (United Paper Mills Ltd). These merged to form UPM-Kymmene in 1996. | | Founding year | Group formed by merger in 1996. The predecessor Kymmene mill company dates to 1872 (historical date, not re-verified in this pass). | | Incorporation jurisdiction | Finland | | Headquarters | Alvar Aallon katu 1, FI-00100 Helsinki, Finland (UPM Head Office; address per company materials, not re-verified this pass). Switchboard +358 204 15 111. | | Stock exchange / ticker | Nasdaq Helsinki: UPM. Secondary trading on Xetra/Frankfurt (ticker RPL, WKN 881026) and US OTC (ordinary shares UPMKF; ADR UPMMY, ADR status not re-verified). | | ISIN | FI0009005987 | | CUSIP | Not applicable to the Helsinki ordinary share. | | Fiscal year end | 31 December | | Shares registered (31 Dec 2025) | 527,735,699. Treasury shares 411,653 (0.08%). | | Employees (end of period) | 15,184 at 30 Jun 2026 (UPM total), of which 13,665 continuing and 1,519 Plywood. 15,127 at end-2025; 15,827 at end-2024; 16,573 at end-2023. | | Average employees | 15,802 (2025); 16,282 (2024); 17,109 (2023) | | Statutory auditor | Ernst & Young Oy, auditor since FY2024 after mandatory rotation; PwC served previously. Lead partner Mikko Järventausta (KHT) from 9 April 2026; Heikki Ilkka for FY2024–FY2025. Re-elected for FY2027. | | Market capitalisation (current) | Approx. €11.8–12.3 bn. This rests on recent third-party snapshots of €22.46–23.48 per share × ~527.3m shares outstanding. Börse Express put market cap at €12.07 bn at €22.62 in mid-July 2026. A live quote should be confirmed. | | Website | www.upm.com (investors: www.upm.com/investors; demerger: www.upm.com/demerger) | | Credit ratings | S&P: BBB / Stable / A-2 (downgraded from BBB+ on 3 Oct 2025). Moody's: Baa1 (latest credit opinion reviewed dates from Dec 2021; current outlook not re-verified). | The entity profiled is UPM-Kymmene Oyj (English: UPM-Kymmene Corporation), a Finnish public limited company listed on Nasdaq Helsinki. It matches the requested name exactly. The requested company type ("Public company") is correct. | Metric | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---| | Personnel at end of period (headcount) | 17236 | 16573 | 15827 | 15127 | | Average personnel (headcount) | 17176 | 17109 | 16282 | 15802 | UPM is a Finnish "material solutions" company built on renewable fibres from managed forests and eucalyptus plantations. It converts wood into market pulp, label and specialty papers, self-adhesive label materials, graphic papers, advanced biofuels and next-generation biochemicals. Through hydro and nuclear holdings it is also Finland's second-largest electricity producer. Sales were €9.66 bn in FY2025. The two Uruguayan pulp mills, including the 2.1 Mt Paso de los Toros mill commissioned in 2023, give UPM one of the lowest-cost eucalyptus pulp platforms globally. Its Finnish operations face structurally high wood costs. UPM is now mid-way through its most significant portfolio reshaping since the 1996 merger: - It is contributing its entire Communication Papers business to a 50/50 joint venture with Sappi. - It is demerging Plywood as a separately listed WISA Group. - It is ramping up the first-of-its-kind Leuna biorefinery. Post-transaction UPM would be a narrower, less paper-exposed group concentrated on fibres, advanced materials and decarbonisation solutions. Management argues this mix grows faster than GDP. --- ### Company's own description In its 2025–2026 boilerplate, UPM describes itself as "a material solutions company, renewing products and entire value chains" with a portfolio of renewable fibres, advanced materials, decarbonization solutions and communication papers. Its tagline is "UPM – we renew the everyday" (UPM releases, 2026). The FY2025 Financial Statements Release defines the reporting segments as follows: **UPM Fibres:** pulp and timber. **UPM Energy:** cost-competitive, zero-carbon electricity, plus physical and financial portfolio management and services to industrial consumers. UPM states it is Finland's second-largest electricity producer. **UPM Adhesive Materials:** (formerly UPM Raflatac): self-adhesive paper and film products, including label materials, graphics solutions and removable products. It is described as the world's second-largest producer of self-adhesive label materials. **UPM Specialty Papers:** renamed UPM Specialty Materials from 1 January 2026. **UPM Communication Papers:** - UPM Plywood: WISA® plywood and veneer. **Other operations:** ### Business model and revenue model | Model type | Businesses | Pricing basis | Earnings drivers | |---|---|---|---| | Commodity / spot-index linked | UPM Pulp (NBSK, BHKP/eucalyptus, birch), UPM Timber, UPM Energy (electricity) | Market indices (FOEX/PIX for pulp; Nord Pool Finland area spot and forwards for power) | Price × volume minus cash cost; UPM states a €50/t pulp price change ≈ €180–270m annual comparable EBIT; €10/MWh Finnish power price change ≈ €40m | | Converted / branded specialty | UPM Adhesive Materials, UPM Specialty Materials, WISA Plywood | Negotiated price lists, mix and grade premiums, some contract pricing | Margin management against pulp, film, adhesive, chemical and energy input costs; commercial excellence | | Structurally declining commodity | UPM Communication Papers | Quarterly or half-year contract and list prices with publishers, printers and merchants | Capacity closures, cost-out, energy refunds; cash generation | | Policy-premium decarbonisation | UPM Biofuels (BioVerno), UPM Biochemicals (Leuna) | Advanced-fuel "bio-premium" under EU RED III and national GHG quotas; brand-owner premiums for bio-glycols and fillers | Regulatory demand, feedstock (crude tall oil) cost, ramp-up execution | UPM's revenue is almost entirely product sales. There is no material subscription or licensing income. Services are a small component, mainly UPM Forest services to private forest owners and UPM Energy's portfolio and industrial-consumer services. Four model types coexist: **Value-chain position.** UPM is vertically integrated from forest to finished product: - It owns and leases forest land in Finland and plantations in Uruguay. Uruguayan plantations owned, leased or managed totalled 505,159 hectares at end-2023 (FS Release 2023). - It produces pulp, consumed internally and sold externally; UPM is a net seller of pulp. - It owns hydro capacity and holds stakes in nuclear generation. - It converts fibre into papers, labels and plywood. S&P (Feb 2025) notes that UPM sources about a third of its wood from its own forests, is largely energy self-sufficient and is a net pulp seller. **Customer types:** - Tissue, board and specialty paper makers (pulp buyers, notably in China and Europe). - Label printers and converters. - Brand owners in food, beverage, home and personal care, and pharma (label end-use). - Publishers, catalogue retailers, printers and paper merchants. - Construction, vehicle-flooring and LNG-shipbuilding firms (plywood). - Fuel distributors and oil majors (biofuels). - Chemical, textile, packaging and tyre/rubber companies (biochemicals). - Grid and industrial energy consumers (energy). **End-markets:** consumer packaging and labelling, tissue and hygiene, print media and advertising, office printing, construction and industrial, transport fuels, specialty chemicals, and the Nordic electricity market. ### Independent characterisation UPM is best understood as three overlapping companies: 1. A low-cost pulp-and-energy cash engine: Uruguay pulp plus Finnish hydro and nuclear. 2. A mid-margin advanced materials converter: labels and specialty papers, roughly €3 bn of sales. 3. A legacy graphic paper business in managed decline, which is being deconsolidated via the Sappi JV. Overlaying these is a venture-style option portfolio in biofuels and biochemicals. Its flagship, Leuna, has cost €1.335 bn and has already absorbed a €373m impairment. Earnings quality is low by design. Comparable EBIT swung from €2,096m (FY2022) to €1,013m (FY2023) and €921m (FY2025), driven chiefly by pulp and electricity prices. Fair-value changes in forest assets (+€144m in FY2025) and seasonal energy refunds in Communication Papers further distort quarterly earnings. The 2025–2026 portfolio actions are an explicit attempt to raise margins, reduce cyclicality and re-rate the equity. Execution, and the European Commission's merger review, will determine whether that succeeds.

Revenue$10.9B
Employees15,184
Market CapN/A
Founded1996
FI-Helsinki, Finland
UNID

UNID Co. Ltd.

Premium
Information Technology

UNID is the world's largest producer of industrial potassium chemicals, principally potassium hydroxide (KOH, caustic potash) and potassium carbonate (K₂CO₃). It makes them by electrolysing imported potassium chloride (KCl) in membrane chlor-alkali cells. Its manufacturing base spans Ulsan, South Korea, and three Chinese sites (UJC and OJC in eastern China, and UHC in Yichang, Hubei). Consolidated KOH-equivalent capacity was about 810,000 tonnes a year after the 2024–25 expansions. The Korean business is export-oriented, with roughly 77–90% of sales shipped overseas, mainly to Asia, India, Europe and Latin America. The Chinese business sells mostly into China's domestic market. End markets include potash fertilisers (potassium phosphates and nitrates), agrochemicals, food additives, pharmaceuticals, rubber latex, glass, solar cells, and carbon capture via the hot-potassium-carbonate process. Co-products such as chlorine, hydrochloric acid, hypochlorite and hydrogen are a structural earnings swing factor. The stock trades at about 0.35x book, a historical trough. --- ### Company self-description UNID describes itself as a potassium-based chemicals specialist. In investor materials, it presents itself as the global market-share leader in potassium chemicals. Its product slate covers: - potassium hydroxide (liquid and solid/flake); - potassium carbonate; - chlor-alkali co-products: hydrochloric acid, liquid chlorine, sodium hypochlorite, ferric/ferrous chloride and hydrogen; - in China, chlorinated paraffin wax (CPs), a downstream chlorine-consuming product. The company lists its applications as: - agricultural pesticides; - petrochemicals; - fertilisers; - pharmaceuticals; - SBR/NB latex; - solar cells; - plastic polymerisation promoters; - animal feed; - gas refining; - glass; - food additives; - household bleach; - metal surface treatment; - water treatment. ### Independent characterisation UNID is best understood as a spread business on the KOH/K₂CO₃–KCl differential, with a chlorine by-product overlay. Electrolysing one tonne of KCl yields KOH plus roughly 0.6 tonnes of chlorine and some hydrogen. The economics therefore depend on four variables: 1. **The potassium chain spread.** Selling prices for KOH and K₂CO₃ track potash (KCl) prices with a lag, so the spread widens when KCl prices rise and buyers stockpile. Brokers measure this as a one-month-lagged spread. 2. **Chlorine realisation.** This matters most in China, where chlorine prices were negative for long periods. Jiangsu chlorine was about –750 yuan/t in early 2025, averaged about –132 yuan/t in 2025, and spiked to about +300 yuan/t on 21 January 2026 (Hana, January 2026). Hana estimates that each +100 yuan/t move in chlorine adds about KRW 5 bn to annual operating profit. 3. **Electricity costs.** Electricity is the dominant conversion cost of electrolysis. Korean industrial tariff hikes have repeatedly hurt third-quarter results. 4. **Ocean freight and FX.** Most Korean output is exported. Freight spikes, such as the 2Q26 Iran-war-related surge, compress margins, and a weaker won helps them. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | ~100% product sales of commodity and specialty inorganic chemicals; no meaningful service, subscription or licensing revenue | | Value-chain position | Midstream converter: buys KCl (largely Canadian potash, e.g. Canpotex, per IBK) and sells potassium derivatives to fertiliser formulators, chemical processors, food and pharma companies, and glass and rubber makers | | Customer types | Industrial B2B: specialty-fertiliser producers (potassium phosphate/nitrate), agrochemical formulators, food processors, pharmaceutical firms, latex/rubber makers, glass and solar producers, water-treatment operators, gas-treating/CCS operators | | Geographic model | Korea entity exports (~77% of 2023 sales per Hanwha; ~90% export share cited by UNID in July 2024 press). China entities sell overwhelmingly domestically (Hana, April 2025) | | US exposure | ~7% of Korea-entity sales go to the US (Hana, April 2025), limiting tariff exposure | | Cyclicality | Linked to the potash cycle, agricultural demand, and industrial demand in China and India | | Seasonality | Typically stronger in the first half and weaker in the second (상고하저): Q2 is the peak season, while Q3 suffers higher Korean summer power tariffs and Chinese chlorine weakness, and Q4 carries annual maintenance | ### End-markets served | End-market | Products | Commentary | |---|---|---| | Specialty fertilisers / agriculture | KOH, K₂CO₃ | Largest growth driver; potassium phosphate and nitrate production; demand from India and Latin America cited repeatedly by brokers | | Agrochemicals | KOH | Pesticide synthesis | | Food and feed | KOH, K₂CO₃ | Food additives, animal feed | | Pharmaceuticals | KOH | Reagent and synthesis | | Rubber / latex | KOH | SBR/NB latex (including glove-latex chains) | | Glass, solar and electronics | K₂CO₃, KOH | Specialty glass, solar-cell texturing/cleaning | | Gas treating / carbon capture (CCS) | K₂CO₃ | Hot-potassium-carbonate (Benfield-type) CO₂ capture; brokers frame CCS as a medium-term re-rating option | | Water treatment / bleach | NaOCl, ferric chloride, HCl | Domestic co-product outlets | | PVC/plasticiser chain (China) | CPs | Chlorine sink in China; plant operating since 2H24 |

Revenue$0.9B
Employees237
Market CapN/A
Founded1980
Seoul, South Korea
Ultramarine

Ultramarine & Pigments Ltd.

Premium
Information Technology

| Field | Detail | |---|---| | Legal name | Ultramarine & Pigments Limited | | Former names | None identified in available records | | Founding / incorporation | Incorporated October 1960 (25 October 1960 per IIFL company summary) in Bombay (now Mumbai); operations commenced 1961 (ICRA rationale, Oct 2025) | | Incorporation jurisdiction | Maharashtra, India (CIN: L24224MH1960PLC011856, per company letterheads in BSE filings) | | Registered office | Thirumalai House, Plot No. 101-102, Road No. 29, Near Sion Hill Fort, Sion (East), Mumbai 400 022, Maharashtra, India | | Principal operating office / works | No. 556, Vanagaram Road, Ambattur, Chennai 600 053, Tamil Nadu, India | | Stock exchanges & tickers | BSE Ltd: scrip code 506685; National Stock Exchange of India: symbol ULTRAMAR | | ISIN | INE405A01021 | | CUSIP | Not applicable (no US listing) | | Face value | ₹2 per share (split from ₹10 to ₹2 with a bonus issue, record date 18 October 2005) | | Paid-up equity capital | ₹584 lakh as at 31 March 2026 (≈2.92 crore shares of ₹2 each) — FY2026 Directors' Report | | Fiscal year end | 31 March | | Employees (latest) | 1,256 permanent employees at end-FY2026 (624 in manufacturing; 632 in ITeS) — derived from gender-ratio disclosures in the FY2026 Directors' Report. Morningstar lists 1,072 (date of data not stated). 3-year trend: not publicly disclosed in sources reviewed | | Statutory auditor | Sundaram & Srinivasan, Chartered Accountants, Chennai (FRN 004207S), appointed at the 63rd AGM on 25 July 2024 for a five-year term | | Cost auditor | GSVK & Co., Cost Accountants (FY2027) | | Internal auditor | M.S. Krishnaswamy & Co., Chartered Accountants | | Secretarial auditor | R.M. Mimani & Associates LLP (five-year term from the 65th AGM) | | Registrar & transfer agent | Cameo Corporate Services Ltd, Chennai | | Market capitalisation (current) | ≈₹1,198 Cr at a share price of ₹410.10 (NSE close, 7 October 2026, per 5paisa) | | Credit rating | [ICRA]A+ (Stable) long-term / [ICRA]A1+ short-term, reaffirmed 7 October 2025 | | Website | https://ultramarinepigments.net | | Promoter group | Sampath / Parthasarathy family; related listed company Thirumalai Chemicals Ltd (TCL) | | Listing status vs. input | Input "Public company" — confirmed. Listed on BSE and NSE; small-cap. | The entity profiled is Ultramarine & Pigments Limited (commonly abbreviated "UPL" in its own filings and by ICRA; not to be confused with UPL Ltd, the agrochemical company). The name and the company type supplied ("Public company") are both correct: this is an active, publicly listed Indian company. No name-matching substitution was required. Ultramarine & Pigments Limited is a six-decade-old, promoter-controlled Indian chemicals company headquartered legally in Mumbai and operationally in Chennai. Its core identity is as one of India's largest producers of ultramarine blue (Pigment Blue 29), an inorganic pigment used across plastics, paints, coatings, cosmetics, inks, laundry whitening and building applications, with adjacent lines in ultramarine violet and pink, bismuth vanadate yellow and complex inorganic colour pigments (CICPs). By revenue, however, the company is primarily a contract-style sulphonation and surfactants supplier to large FMCG detergent and personal-care makers in South India, which generated roughly 63% of FY2026 revenue. A smaller but higher-margin IT-enabled services (ITeS) arm handles publishing/content services and healthcare billing. The company is conservatively financed (ICRA gearing ~0.1x), consistently dividend-paying, and is now embarking on its largest pigment capex in history — a ₹250 Cr greenfield plant in Tamil Nadu. --- ### What the company does Ultramarine & Pigments operates three reportable business segments as disclosed in its quarterly segment reporting: (1) Chemicals and Allied Products, which contains both inorganic pigments and surfactants/specialities; (2) IT-Enabled Services (ITeS), including BPO activity; and (3) Windmill (wind power generation), which is primarily captive. Morningstar's business description and the company's Q3 FY2026 filing confirm this three-segment structure. **Inorganic pigments.** The company manufactures ultramarine blues (Pigment Blue 29), ultramarine violet (Pigment Violet 15), ultramarine pink (Pigment Red 259), bismuth vanadate (Pigment Yellow 184), and complex inorganic colour pigments/mixed metal oxides. The company's website emphasises "environmentally friendly" pigments usable across paints, plastics, inks, laundry and cosmetics. ICRA notes that high-grade ultramarine is used in plastics, paints, coatings, cosmetics, food and detergents, while lower grades go into whitewash and laundry applications. Pigments are made at Ambattur (Chennai) and Ranipet in Tamil Nadu by the parent, and at Naidupeta, Andhra Pradesh, by wholly owned subsidiary Ultramarine Specialty Chemicals Ltd (USCL), whose capacity reached 3,550 MTPA after an expansion completed in FY2026. **Surfactants and specialities.** The company is a sulphonator producing linear alkyl benzene sulphonic acid (LABSA), alpha olefin sulphonate (AOS) and sodium lauryl ether sulphate (SLES), plus a growing basket of specialty/cosmetic-grade surfactants: medium chain triglyceride (MCT), benzalkonium chloride (BKC), cocamidopropyl betaine (CAPB), coco mono-ethanolamide (CMEA), coco diethanolamide (CDEA), cocamidopropylamine oxide (CAPAO), disodium laureth sulfosuccinate (DLESS) and lauryl amine oxide (LAO). It also sells detergent powder/liquid under the brand "OOB" (per ICRA). ICRA describes the company as among the key suppliers of surfactants to detergent manufacturers in South India, including large multinational FMCG players. Surfactants are produced at Ranipet (Tamil Nadu) and Naidupeta (Andhra Pradesh). **IT-enabled services.** Started in 2000 under the leadership of current Vice Chairperson Indira Sundararajan, the ITeS division operates from Chennai and Ranipet and is commonly referenced as "Lapiz Digital Services" (third-party listing) alongside a customer/broadcast services unit. ICRA characterises it as specialising in content management, publishing and hospital billing services. In FY2026, ITeS income was ₹52 Cr with segment profit of ₹15 Cr. **Wind power.** The company owns seven wind turbine generators at three Tamil Nadu locations with total capacity of 5 MW (FY2025: 4.3 MW), generating 80 lakh units in FY2026, all captively consumed at the Ranipet and Ambattur plants. ### Business model and revenue model | Revenue model component | Description | FY2026 indicative share of consolidated revenue | |---|---|---| | Product sales — surfactants & specialities | Volume-driven B2B supply to FMCG detergent and personal-care makers; pricing largely linked to feedstock (LAB, alpha olefins, fatty alcohols/ethoxylates) with limited value addition per ICRA | ≈63% (₹489 Cr of ₹775 Cr) | | Product sales — inorganic pigments (parent) | B2B sales to plastics, coatings, inks, cosmetics, laundry and building-materials customers, domestic and export | ≈21% (₹164 Cr) | | Product sales — inorganic pigments (subsidiary USCL) | Ultramarine and CICP output from Naidupeta | ≈10% (₹74 Cr, gross of any intercompany) | | Services — ITeS/BPO | Fee-for-service publishing, content management, healthcare billing | ≈7% (₹52 Cr) | | Captive power | Wind generation consumed internally; small reported segment revenue | <1% | | Subscription / licensing | None | 0% | *Note:* Segment figures are from the FY2026 Directors' Report; shares are derived and sum to slightly more than 100% because subsidiary revenue may include intercompany sales and divisional figures are not reconciled one-for-one with consolidated revenue in the report. ### Value-chain position The company sits in the mid-stream of two chemical chains. In surfactants it converts petrochemical and oleochemical intermediates (LAB, alpha olefins, fatty alcohol ethoxylates, coconut-derived amides) into anionic and amphoteric surfactants sold to consumer-goods formulators — a position with limited pricing power, as ICRA explicitly notes. In pigments it is closer to a specialty manufacturer, converting minerals and commodity inputs (kaolin/china clay, soda ash, sulphur, silica and reducing agents for ultramarine; bismuth and vanadium compounds for BiVaN; metal oxides for CICPs) into finished colorants. ITeS is a separate services value chain. ### Customer types and end-markets | End-market | Products | Customer type | |---|---|---| | Home care / laundry detergents | LABSA, AOS, SLES, OOB detergents, laundry-grade ultramarine | Large MNC and domestic FMCG players, regional detergent makers | | Personal care & cosmetics | SLES, CAPB, amine oxides, DLESS, MCT, cosmetic-grade ultramarine | FMCG and cosmetics formulators | | Plastics & masterbatch | Ultramarine blue/violet, BiVaN, CICPs | Compounders, masterbatch makers | | Paints & coatings | Ultramarine, BiVaN, CICPs | Paint and coatings manufacturers | | Printing inks | Ultramarine grades | Ink makers | | Building materials / whitewash | Lower-grade ultramarine | Construction-chemicals and whitewash makers | | Disinfection / institutional | BKC | Hygiene-product manufacturers | | Publishing & healthcare (ITeS) | Content/publishing services; hospital billing | Global publishers; healthcare providers | ### Company's own description vs. independent characterisation The company describes itself on its website as "a leading manufacturer of inorganic pigments and surfactants" with a legacy of over 60 years, a client base across more than 50 countries, and a focus on quality, certifications (ISO 9001/14001/45001 per letterheads) and social responsibility. Its FY2026 Management Discussion attributes the year's growth to surfactants volumes and realisations, notes that export markets beyond the US offset tariff impacts, and flags rising input costs from West Asia disruptions. **Independent characterisation:** UPL is best understood as a cash-generative, low-leverage surfactant converter with a niche global pigments franchise and a non-core but profitable services arm. Its brand identity rests on ultramarine, but its earnings mass increasingly rests on surfactants, which ICRA flags as low value-add. Margins have structurally reset from 23–25% (FY2019–FY2021) to 16–18% (FY2022–FY2026) as the surfactant mix rose. The balance sheet is dominated by a large equity investment in group company Thirumalai Chemicals, which introduces mark-to-market volatility and governance considerations unrelated to operating performance. The ₹250 Cr Manapparai greenfield is an explicit attempt to re-weight the portfolio back toward pigments.

Revenue$0.1B
Employees1,256
Market CapN/A
Founded1960
Mumbai, India
TrustChem

Trust Chem Co. Ltd.

Premium
Information Technology

Trust Chem is China's largest exporter of organic pigments, ranked first in national organic-pigment exports every year from 2015 to 2025 by the Organic Pigment Committee of the China Dyestuff Industry Association. Historically an asset-light "colourant solutions" house, it combines application-driven product development, proprietary testing and quality control, upstream supply-chain integration and a global, localised sales and warehousing network across 70–80+ countries, selling more than 450 pigment specifications under its own brand to multinational ink, coating and plastics producers such as DIC, Flint Group, Siegwerk, Sherwin-Williams and Axalta. Roughly 80–88% of revenue is earned outside China. Since 2023 it has been moving upstream into owned manufacturing through two subsidiaries in Jinzhou, Liaoning, and its July 2026 convertible-bond plan (≤ CNY 450M) would fund high-performance post-treatment capacity. The investment case hinges on whether vertical integration can lift structurally thin (~15–18%) gross margins without eroding its trading-model agility. --- ### Company's own description (2026 Interim Report, Section III) The company states that it is principally engaged in the product development, production, sale and servicing of organic pigments and other colourants. Its core competitiveness is defined as product development, quality management, supply-chain integration and a global sales network. Main products are organic pigments (azo, heterocyclic, phthalocyanine and others) and acid dyes. Organic pigments are applied in inks, coatings, plastics and specialty applications; acid dyes are used for dyeing textile fibres (nylon, wool, silk and blends), inkjet inks and waterborne wood lacquers. The company emphasises that downstream application diversity, customer habits and regional differences create extensive demand for customised and personalised pigment products, and that large international customers impose stringent requirements on application development capability, quality, management systems, compliance, geographic coverage and responsiveness. The stated operating model is a five-link chain: (1) obtain and analyse customer requirements; (2) develop products; (3) manage the supply chain; (4) test products and control quality; (5) sell under the company's own brand. ### Operating sub-models **Procurement:** Because no single pigment manufacturer can cover the breadth of downstream needs, Trust Chem integrates upstream suppliers who produce to its specifications, and maintains a "qualified supplier list" refreshed through periodic assessments. Per the IPO risk disclosure, purchased finished pigments accounted for 94.88% (FY2021), 93.05% (FY2022), 93.64% (FY2023) and 88.94% (1H2024) of main-business cost — demonstrating that the company has been overwhelmingly a branded integrator rather than a manufacturer. **Sales:** Predominantly export-led, combining a Hangzhou headquarters sales team with localised overseas teams. Orders flow through an ERP system to procurement and technical service; product-development requests go to R&D. The company maintains overseas warehousing so it can serve safety-stock requirements and deliver quickly. **R&D:** A synthesis laboratory (new pigment development) and application laboratories for coatings, plastics and inks that simulate customers' use conditions. New-product development follows a project-team model led by R&D with multi-department participation, staged from demand investigation through feasibility, design, sampling, testing, review and acceptance. **Own production:** Described as a "supplement and improvement" to the supply chain — validating R&D projects at the company's own production bases before supply. The Jinzhou (Liaoning) bases are positioned in the CB filings as the group's "technology transformation base for high-quality, high-value-added, safer and more environmentally friendly products." ### Revenue model and mix | Dimension | Characterisation | |---|---| | Product vs. service | ~99% product sales (chemical industry); "other business" 0.96% of 1H2026 revenue | | Subscription / licensing | None disclosed | | Pricing basis | Transactional, quoted in USD/EUR for exports; forward FX quoting used to pass through currency risk | | Revenue recognition | FOB/CIF/CFR on bill of lading; DDU/DAP/DDP on customer receipt; consignment on monthly reconciliation (2026 Interim Report, Note V.37) | | Customer concentration | Top-5 receivables = 32.66% of receivables at 30 Jun 2026 (largest 12.47%) | ### Value-chain position Trust Chem sits between Chinese pigment producers (upstream: petrochemical and coal-chemical intermediates → pigment synthesis) and multinational formulators (downstream: printing inks, industrial and decorative coatings, plastics masterbatch). Its value-add is specification design, application testing, regulatory compliance (REACH, MSDS in ~30 languages), brand assurance and logistics. It is now adding a manufacturing layer (azo dyes/pigments and high-quality organic pigments in Jinzhou) and, if the CB is completed, a post-treatment ("high-performance-isation") layer that would upgrade both self-made and outsourced pigments. ### Customer types and end-markets | End-market | Application | Representative customers named in filings | |---|---|---| | Printing inks | Packaging, publication, specialty inks | DIC Corporation, Flint Group, Siegwerk | | Coatings | Industrial, decorative, automotive refinish | Sherwin-Williams, Axalta | | Plastics | Masterbatch, compounds | Not named | | Textiles (acid dyes) | Nylon, wool, silk dyeing | Not named | | Specialty | Inkjet inks, waterborne wood lacquers, stationery | Not named | The CB feasibility report (Jul 2026) states core customer relationships exceed ten years and switching costs are high. ### Independent characterisation Trust Chem is best understood as a global specialty-chemicals distributor-integrator with brand and compliance moats, in transition toward partial vertical integration. Its gross margins (~14–18%) are closer to a sophisticated distributor than to a pigment manufacturer (domestic HPP producers such as Qicai Chemical report ~29% gross margin), but its returns on equity were historically high (derived ~17–22% in FY2022–FY2024) because the model was capital-light. The pivot to owned manufacturing in Liaoning has raised the asset base (total assets up from CNY 983M in FY2021 to CNY 2,026M at 1H2026) while the manufacturing subsidiaries have so far been loss-making (Liaoning Xinkai net loss CNY 24.97M in FY2024), compressing ROE (derived ~9.5% in FY2025). The core strategic question for investors is therefore one of capital allocation: whether manufacturing brings margin uplift and supply security commensurate with the capital and execution risk.

Revenue$0.2B
Employees445
Market CapN/A
Founded1996
Zhejiang, China
Troy

Troy Corporation

Premium
Information Technology

Troy Corporation is one of the original American specialists in industrial microbial control. For more than seven decades it built a niche franchise in preservatives and performance additives that protect paints, coatings, building materials, wood, plastics, textiles, metalworking fluids and personal care products from microbial spoilage and fungal or algal defacement. Its defining technical legacy is the invention of IPBC (3-iodo-2-propynyl butyl carbamate), now one of the world's most widely used dry-film fungicides. It sold IPBC under the Polyphase brand alongside the Mergal wet-state preservative family and a broad additives line (Troykyd defoamers, Troysol wetting agents, Troysperse dispersants, Troythix rheology modifiers, Troymax/Troychem driers). The 2015 purchase of Ashland's industrial biocides assets added the Fungitrol and Nuosept brands. Since January 2022 Troy has formed the dry-film and architectural-coatings core of Arxada's Microbial Control Solutions franchise. That gives it a much larger balance sheet and active-ingredient portfolio, but it also exposes the business to the parent's leveraged capital structure, which was restructured in 2026. --- ### What the company does Troy develops, registers, manufactures and sells specialty chemicals in three broad families: 1. **Preservatives / biocides (microbial control)** - *Dry-film preservatives*, which protect a cured coating, sealant or building product from mould, mildew and algae after application (Polyphase, Fungitrol, Troysan). - *Wet-state (in-can) preservatives*, which protect water-based products from bacterial and fungal spoilage in the container (Mergal, Nuosept). - *Metalworking fluid (MWF) bactericides and fungicides*, together with microbial contamination test kits. - *Industrial disinfectants* and microbial detection kits. 2. **Performance additives** for liquid and powder coatings, inks and adhesives: defoamers, substrate-wetting, flow and levelling agents, dispersants, rheology modifiers and powder-coating additives. 3. **Metal carboxylates**, meaning driers, anti-skinning agents and urethane catalysts for oxidatively curing coatings and some lubricant applications. Aggregator profiles describe the range as fungicides, algaecides, dispersants, defoamers, bactericides, wetting agents, rheology modifiers, flow and levelling agents, microbial detection kits, industrial disinfectants, powder coating additives, driers and urethane catalysts (Craft company summary). Lubes'n'Greases (November 2021) reported that Troy produced more than 400 preservatives, performance additives and metal carboxylates at manufacturing facilities on three continents. ### The company's own description Before the merger, Troy described itself as developing and manufacturing "specialty materials that enhance the properties and performance of its customers' products and processes." It also emphasised a commitment to helping manufacturers meet global compliance and sustainability requirements, sales offices across the US, Canada, Europe, Asia and Latin America, and availability in more than 100 countries (Troy boilerplate in Ashland's press release, 1 July 2015). Arxada's merger announcement (5 January 2022) characterised Troy as a global leader in industrial preservation. It cited expertise in paints and coatings, wood protection and preservation, home and personal care, plastics and textiles, energy, and metalworking fluids, and highlighted Troy's invention of IPBC. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | Almost entirely product sales (B2B specialty chemicals sold by the kilogram or tonne). Technical services such as microbiological challenge testing, field exposure testing, regulatory support and the "TMMA" microbial management programme are bundled to win and defend specifications rather than billed as material standalone revenue. No subscription or licensing revenue model has been disclosed. | | Product vs service mix | Mostly product. The service share is n/d. | | Value chain position | Mid-stream. Troy synthesises or formulates active ingredients (notably IPBC) and blends multi-active preservative packages, then sells them to formulators (paint, coatings, adhesives, MWF and personal care manufacturers), who embed them in finished goods at low dosage, typically well under 1% of formulation. | | Pricing power drivers | Regulatory registrations (US EPA FIFRA, EU BPR, GB BPR), long qualification cycles at customers, formulation-specific efficacy data, and a very low share of the customer's bill of materials. | | Customer types | Architectural and industrial paint makers; construction products, adhesives, sealants and grout producers; wood treaters; plastics and textile processors; MWF and lubricant blenders; personal and home care formulators; ink and pigment-dispersion makers; paper producers. | | End-markets | Paints and coatings (largest, based on Troy's own emphasis on "architectural coatings and industrial preservation"), building products, wood protection, adhesives and sealants, metalworking fluids and lubricants, plastics, textiles, personal care, inks, paper. | ### Independent characterisation Troy is best understood as a regulatory-moat niche chemical franchise. The economic value rests less on manufacturing scale than on its portfolio of registered active substances and the efficacy dossiers supporting them. Re-registering or newly registering a biocidal active in the EU or US can take years and cost millions of dollars per substance. That keeps entry barriers high and the competitor set concentrated. Troy's distinctive asset was IPBC know-how. Arxada stated that it did not manufacture IPBC before the deal (Cinven / Arxada announcement, 3 November 2021). Troy therefore filled a specific gap: dry-film protection for architectural coatings, which complemented Arxada's legacy strength in wet-state preservation (Daryl Smith, Troy CEO, quoted by Lubes'n'Greases, November 2021).

RevenueN/A
Employees650
Market CapN/A
Founded1950
NJ, US
Trillium

Trillium Ag

Premium
Information Technology

Trillium Ag is a Washington State agricultural biotechnology platform company founded in 2016. It is trying to solve the problem that has kept RNA interference from becoming a mainstream crop-protection category: naked double-stranded RNA breaks down quickly, crosses membranes poorly, and most economically important insect pests do not respond to it when they ingest it. The company's Agrisome platform takes a different approach to each of these problems. It uses a single-stranded, structurally engineered RNAi trigger. It packages that trigger in programmable protein nanoparticles, which can also be loaded into engineered exosomes and stabilised in natural crystals for field use. AI-assisted sequence and particle design tools sit on top. Trillium does not intend to become a vertically integrated pesticide maker. Its plan is to be an enabling-technology licensor and co-development partner to established crop-protection companies. A second business, the nPlanta plant-based cell-free protein expression kit, gives it an early source of product revenue and a research tool that also has customers in pharma and biotech. --- ### What the company does Trillium Ag develops biological crop-protection technology based on RNA interference. RNAi is a natural cellular process in which a short RNA sequence matching a target gene leads to that gene's messenger RNA being destroyed, which silences the gene. Silencing a gene essential to a pest's survival can kill the pest, or stop it feeding or reproducing. Because the sequence can match genes found only in the target species, the method is potentially far more selective than broad-spectrum synthetic chemistry. The company's website states its long-term ambition plainly: crop protection that defends yields without damaging the surrounding ecosystem. It says Agrisome addresses insects, weeds, fungi and other pests. The only disclosed proof-of-concept (POC) data, however, cover three insect orders: Lepidoptera (moths and caterpillars), Coleoptera (beetles) and Hemiptera (true bugs such as aphids and stink bugs). ### Company's own description (paraphrased; no annual report exists) Trillium Ag has no annual report. Its self-description on trillium.ag, accessed October 2026, is the closest substitute. In paraphrase, the company says it develops new biological platforms for more precise and sustainable crop protection, and that its nature-inspired, AI-designed Agrisome platform has finally delivered on RNAi's potential against insects, weeds, fungi and other pests. It says it is currently helping partner companies build a new class of field-ready biological protectants. An older directory description, carried over from the company's earlier materials, describes a portfolio of RNAi-based biologicals for crop protection, plant health and yield. That portfolio rested on a patented RNAi trigger called MV-RNA (cited as US Patent 9,200,276) and on nanoparticles for transient or stable trait activation (VisualVisitor profile). ### Independent characterisation Trillium Ag is a pre-commercial, IP-led platform biotech. Its economics depend on licensing and partnering, much like a pharma drug-discovery platform. Its development path is long, regulated and capital-hungry: discovery, then greenhouse trials, then field trials, then regulatory registration (EPA under FIFRA in the US, with equivalent agencies elsewhere), then commercial launch. Each stage can take years. The company's public positioning moved over 2023–2026: **2023:** "Agrisome" was described as a protein-coated RNA biological that Trillium intended to take from R&D to broad-acre use. **2026:** Trillium describes itself as a partner-enablement platform. It offers platform licences, co-development programmes, and licence-ready compositions, and it has added AI design tools and a proprietary bioproduction system (nPlanta). The direction of travel is from "we will make products" towards "we make the toolkit and the IP that major crop-protection companies will license." This is a capital-light strategy that suits a very small team. ### Business and revenue model | Revenue model element | Description | Status | |---|---|---| | Platform licensing | A partner receives broad access to the Agrisome platform across products and categories | Offered (website); no disclosed signed licences | | Co-development | Trillium runs specific programmes with a partner to feed the partner's development pipeline; typically funded R&D plus milestones and royalties (industry norm; Trillium's terms n/d) | Offered; trade press (2023) cites "several ongoing collaborations" with unnamed commercial and academic partners | | Composition licensing | Licence-ready proof-of-concept compositions against Lepidoptera, Coleoptera and Hemiptera targets | Offered | | Product sales – nPlanta | Cell-free protein expression lysate, reaction buffers, vectors and scalable formats, sold through an e-commerce storefront (shopping cart and account login on nplanta.com) | Commercial; revenue n/d | | Mix (product / service / licensing) | Not publicly disclosed | n/d | ### Value-chain position Trillium sits at the very start of the crop-protection value chain, in upstream discovery and enabling technology. Downstream are: 1. Agrochemical and biologicals majors (Bayer, Syngenta, Corteva, BASF, FMC, UPL and others), which handle development, registration, manufacturing and distribution. 2. Ag retailers and distributors. 3. Growers. nPlanta places Trillium in a second value chain as well: life-science research tools, where it sells to R&D labs in medicine, agriculture and biotechnology. ### Customer types and end-markets | Customer type | Offering | End-market | |---|---|---| | Global crop-protection companies | Platform / co-development / composition licences | Insecticides and biopesticides; potentially fungicides and herbicides | | Seed and trait companies | Crystal formats described as compatible with seed traits | Seed treatments and traits | | Academic research partners | Collaborations (unnamed) | Research | | Pharma, biotech and ag R&D labs | nPlanta cell-free expression kits | Protein expression and research reagents |

RevenueN/A
Employees3
Market CapN/A
Founded2016
Washington, US
Transportadora

Transportadora de Gas del Norte S.A.

Premium
Information Technology

The StockAnalysis figure of 522 differs materially from the Revelio estimate. The gap may reflect different definitions (for example, permanent staff versus all workers including contractors) and is unresolved. TGN is one of Argentina's two licensed trunk natural-gas transporters and the dominant midstream carrier for the centre and north of the country. It operates and maintains about 11,317 km of high-pressure pipelines and 22 compressor plants through two systems: - the Norte system, originally built to bring gas south from Salta and Bolivia; and - the Centro Oeste system, which carries Neuquén Basin (Vaca Muerta) gas towards Córdoba, Santa Fe and the Litoral. TGN moves roughly 40% of the gas injected into Argentina's trunk network. Its system also connects to export pipelines into Chile (GasAndes, Gas del Pacífico, NorAndino), Brazil (Uruguayana/TGM) and Uruguay (Entrerriano). These links position TGN as the natural conduit for Vaca Muerta gas heading to northern Argentina and to regional export markets. The company combines a regulated, tariff-based core with a small unregulated pipeline O&M and engineering business. After two decades of frozen tariffs, debt restructuring and state intervention, TGN emerged in 2024–2025 with rising tariffs, a strong net-cash balance sheet and renewed dividend capacity. --- **What the company does.** TGN provides firm and interruptible transportation of natural gas through high-pressure pipelines under a federal public-service licence regulated by ENARGAS (Ente Nacional Regulador del Gas). ENARGAS is being merged into a unified gas-and-electricity regulator created by Decree 452/2025. TGN does not own the gas it carries. Its customers ("cargadores", or shippers) contract pipeline capacity and pay a regulated tariff. That tariff is a capacity reservation charge for firm service plus usage charges, and TGN also retains a percentage of gas for compressor fuel. **Revenue model.** Revenue is overwhelmingly service-based and regulated: Source: TGN FY2024 results filed with the CNV, as reported by LM Neuquén (Mar 2025). The regulated revenue has two components: **Domestic transportation (ARS-denominated):** Tariffs are set by ENARGAS through five-year tariff reviews (RQT). The latest review, for 2025–2030, was approved in April 2025. Since June 2025, tariffs have also been adjusted monthly through a formula combining the wholesale price (IPIM), construction-cost (ICC) and wage (IS) indices. **Export transportation (historically USD-denominated):** Under Decree 689/2002, tariffs for capacity serving export contracts were exempt from the 2002 pesification of tariffs and contracts. As a result, export revenue rose in pesos whenever the peso depreciated. Decree 580/2026 (8 July 2026) repealed Decree 689/2002, removing this USD tariff treatment. This is a material structural change to the export revenue model. The non-regulated services provide pipeline operation, maintenance, integrity, hot-tap and connection, engineering, project management, SCADA/communications, damage prevention and training to third-party pipelines. According to StockAnalysis's profile, these services are provided in Argentina, Chile, Mexico, Peru and Uruguay. **Value-chain position.** TGN is pure midstream. Its system sits between producers and the next link in the chain: **Upstream (gas supply):** Neuquén Basin/Vaca Muerta producers such as YPF, Tecpetrol, TotalEnergies, Pampa, Pan American and CGC, plus the declining Noroeste Basin, and historically Bolivian imports. **Downstream (gas offtake):** - distribution licensees, for example Gasnor, Gas NEA, Distribuidora de Gas del Centro/Cuyana (Ecogas), Litoral Gas, Naturgy BAN and Metrogas; - thermal power plants (through CAMMESA and generators); - large industrial users; - export pipelines. **Customer types.** - Gas distribution companies, which hold the largest share of firm capacity. - Power generators. - Producers and marketers, including export shippers. - Industrial direct-connected users. - ENARSA (Energía Argentina S.A.), the state energy company. ENARSA holds contracts linked to the Bolivian import contract and owns the Perito Moreno pipeline (formerly GPNK). **End-markets.** - Residential and commercial heating (highly seasonal, with a winter peak). - Power generation. - Industry, including petrochemicals and the emerging NOA lithium mining load. - Exports to Chile, Brazil (via Bolivia) and Uruguay. **Company's own description (paraphrased from recent corporate releases).** TGN describes itself as a regional pipeline operator and provider of reliable solutions for energy projects. It says it operates about 11,317 km of high-pressure pipelines and 22 compressor plants and carries about 40% of the gas injected into Argentina's trunk pipelines through the Norte and Centro Oeste systems. (Source: TGN press release on the CEO appointment, Feb 2026, as published by El Economista and LM Neuquén.) **Independent characterisation.** TGN is a regulated, inflation-indexed, capacity-based toll road. Its economics are driven by three things: 1. The regulatory tariff path, which after the 2024 transitional agreement and the 2025 RQT has moved from deeply sub-economic to roughly cost-reflective. 2. Contracted firm capacity, which is being reshuffled by the 2026 "reconfiguration" of the national transport system. 3. Export volumes, which grew 23% in 2025 to 2,200 MMm³. Operating leverage is very high because most costs are fixed. This is why the tariff normalisation of 2024–2025 swung EBITDA from negative to above 50% margins. The business is now in a strategic transition. The Norte pipeline is being converted from a south-bound import route into a north-bound conduit for Vaca Muerta gas, which opens a potential role as a regional "gas bridge" to Bolivia, Brazil and northern Chile.

RevenueN/A
Employees1,076
Market CapN/A
Founded1992
Buenos Aires, Argentina
Trécé

Trécé Inc.

Premium
Information Technology

Trécé, Inc. is a vertically integrated, founder-owned American specialist in insect semiochemicals — pheromones and kairomones — that occupies a distinctive niche between agrochemical majors and biological-control start-ups. Founded in Salinas, California in the early 1980s and relocated to its founder's hometown of Adair, Oklahoma in 2002, the company synthesises its own active compounds (reportedly over 100 difficult-to-make molecules), formulates controlled-release lures and dispensers, and manufactures traps on site. Its three franchise brands span the integrated pest management (IPM) cycle: PHEROCON for detecting and timing agricultural pests in orchards, vineyards and row crops; STORGARD for early-warning monitoring in food processing, warehousing and retail; and CIDETRAK for mating disruption that reduces insecticide reliance. Distribution is through specialist agricultural and pest-control channels in more than 50 countries, and exporting is a repeated, award-recognised growth engine. Trécé competes on chemistry depth, behavioural-entomology science and manufacturing agility rather than scale. --- ### Company's own description Trécé does not publish an annual report. Its current self-description (trece.com "About" page, updated July 2026) characterises the company as a leading American innovator in pheromone- and kairomone-based research and development, insect monitoring, mating disruption and control systems, whose PHEROCON, STORGARD and CIDETRAK brands set an industry benchmark for precision and reliability. The homepage (August 2026) stresses the integration of in-house organic chemistry and on-site manufacturing with a dedicated Behavioral Entomology & Chemical Ecology Laboratory that studies real-time insect responses and translates those data into traps, lures and mating-disruption dispensers. The company also describes itself as customer-focused and market-driven, with manufacturing capabilities that support on-demand, just-in-time production. An older corporate boilerplate (CNFA release, June 2018) framed the mission as growing through the development, manufacturing and marketing of pheromone- and kairomone-based products that benefit food production and the environment while creating economic value for customers, employees and communities. ### What the company does Trécé's activity can be separated into four linked capabilities: 1. **Semiochemical synthesis.** In-house chemists synthesise insect sex pheromones, aggregation pheromones and kairomones (host-plant or food-derived attractants). A BioSolutions Conference profile states the company synthesises more than 100 difficult-to-make compounds for the global monitoring market, and runs research programmes in chemical synthesis, process development, and solid and liquid formulation. 2. **Controlled-release formulation.** Actives are loaded into lures (e.g., Long-Life™ L2™ controlled-release lures, SNUGFIT® lure trays), passive dispensers (CIDETRAK "PP" and MESO™ formats), microencapsulated sprayables (CIDETRAK DA MEC® and IMM MEC™) and newer CPD™ dispensers. 3. **Trap and device manufacturing.** Adhesive-based delta, wing and dome traps (PHEROCON VI, STORGARD II/III, DOME, THINLINE III, Transporter, Out-Dor, CR cockroach monitor) are manufactured at Adair. 4. **Technical service and IPM content.** IPM PARTNER® management guidelines, the Field Reporter™ newsletter, a mating-disruption dispenser calculator, scientific reviews and field notes support customers and distributors. ### Business model and revenue model | Revenue model element | Assessment | Evidence | |---|---|---| | Product (consumables: lures, traps, dispensers) | Dominant — effectively 100% of disclosed activity | Product catalogue, trece.com 2026 | | Services (technical support, guidelines) | Bundled / non-monetised support | IPM PARTNER guidelines, Field Reporter | | Subscription | None disclosed | — | | Licensing / royalties | None disclosed | — | | Government / development-aid procurement | Material episodic channel (USAID-funded projects) | CNFA (2018); Export Champion release (2026) | | Revenue mix percentages | Not publicly disclosed | — | Trécé's revenue is overwhelmingly product revenue from consumable devices. Monitoring traps and lures are replaced seasonally (lures typically every several weeks; traps when adhesive surfaces are saturated), and mating-disruption dispensers are deployed once or more per season per acre. This creates a recurring, consumable, season-driven revenue stream that behaves economically like a replenishment model, although it is not contractually a subscription. No licensing, subscription, or service revenue is publicly disclosed; the online ordering portal and distributor channel are transactional. Historic distributor terms (Target Specialty Products price list, 2016) show a USD 250 minimum order, net-30 credit terms, FOB Adair freight terms, USD-denominated pricing, and two-week delivery lead times. ### Value-chain position Trécé is unusually vertically integrated for its size: it spans active-ingredient synthesis (upstream), formulation and device manufacture (midstream), and brand ownership with technical marketing (downstream), while relying on third-party distributors and pest-control-operator (PCO) supply houses for last-mile sales. This contrasts with smaller trap assemblers that buy pheromone from contract synthesisers, and with large agrochemical companies for whom pheromones are a minor sideline. ### Customer types and end-markets | End-market | Typical customers | Primary brands | |---|---|---| | Tree fruit (apple, pear, stone fruit) | Growers, pest control advisers (PCAs), packers | PHEROCON CM/OFM/PTB; CIDETRAK CM, CMDA, OFM-L, LR | | Tree nuts (almond, pistachio, walnut, macadamia, hazelnut) | Growers, farming companies, PCAs | PHEROCON NOW, LFB, BMSB; CIDETRAK NOW MESO, CMDA+NOW, MNB MESO | | Grapes / vineyards | Growers, viticulture advisers | PHEROCON EGVM; CIDETRAK VMB MESO | | Citrus | Growers | CIDETRAK CRS MESO | | Vegetables & specialty crops | Growers | PHEROCON SCCB, WFT, SWD; CIDETRAK DBM CPD | | Nursery / ornamentals | Nurseries, extension services | PHEROCON AMB, HBW | | Food processing, warehousing, retail food | Food manufacturers, mills, warehouses, retailers, QA managers | STORGARD range; CIDETRAK IMM, IMM MEC | | Professional pest control | PCOs, pest control supply distributors | STORGARD (incl. CR cockroach monitor), CIDETRAK IMM | | Government & international development | USAID implementing partners (e.g., CNFA), ministries, quarantine programmes | PHEROCON BMSB and others | | Research | Universities, USDA and international agencies | Full catalogue | ### Independent characterisation Trécé is best characterised as a niche-dominant specialty biorational manufacturer with strong brand equity in two particular arenas — North American tree-fruit/tree-nut monitoring (PHEROCON) and stored-product monitoring for food plants (STORGARD) — and a growing but more contested position in mating disruption (CIDETRAK), where it faces better-capitalised rivals. The company's economic moat rests on chemistry know-how, decades of field efficacy data, registration dossiers for CIDETRAK control products in multiple countries, and entrenched distributor relationships. Its key structural limitations are scale, founder concentration, and exposure to a handful of crop systems (notably California nuts and Pacific Northwest pome fruit).

RevenueN/A
Employees51
Market CapN/A
Founded1982
OK, US
ToyoInkSC

Toyo Ink SC Holdings

Premium
Information Technology

artience is Japan's oldest major printing-ink house, now a diversified specialty-chemicals group with JPY 350bn in annual sales. It is built on three core technologies: pigment and resin synthesis, nano-dispersion, and coating/film formation. The group has repositioned from a printing-ink business, which faces structural decline in domestic publication printing, toward four balanced segments: Colorants & Functional Materials, Polymers & Coatings, Packaging Materials, and Printing & Information. It holds leading positions in LCD color-filter resists, UV-curable inks, gravure/flexo packaging inks and display-grade optical adhesives. A 2024 rebrand ("art" + "science") marked a shift toward electronics, mobility/battery and bio-healthcare materials, notably carbon-nanotube (CNT) conductive dispersions for lithium-ion batteries. Overseas sales are about 55% of the total, spread across China, Southeast Asia, India, Turkey, Europe and the Americas. The investment case rests on margin recovery in the legacy businesses and buyback-driven ROE improvement. The main swing factor is the delayed payoff from heavy EV-battery capex. --- ### What the company does artience is a pure holding company. It sets group strategy and controls operating subsidiaries organised by technology platform: **TOYOCOLOR CO., LTD:** pigments, plastic colorants and functional dispersions. **TOYOCHEM CO., LTD:** adhesives, pressure-sensitive adhesives (PSAs), coatings, functional films and battery-related materials. **TOYO INK CO., LTD:** packaging inks, offset/UV inks and printing systems. **TOYO VISUAL SOLUTIONS CO., LTD:** display materials such as color-filter resists. **Toyo-Morton, Ltd:** laminating adhesives. **TOYO FPP CO., LTD:** gravure cylinder platemaking. - About 47 overseas affiliates. The group's product list covers organic pigments, processed pigments, plastic colorants, LCD color-filter materials, can coatings, resins, adhesives, PSAs, coating materials, natural products, medical products, gravure inks, flexographic inks, gravure cylinders, offset inks, metal-decorating inks, printing machinery and prepress systems, and inkjet materials (company profile page). ### Company's own description (paraphrased from the FY2025 Yuho and Integrated Report) The company describes four businesses. It expands from colorants into energy, electronics and bio-healthcare. It traces its origin to the printing-ink business, which it still regards as important information infrastructure. Its stated mission, under the January 2024 philosophy refresh, is to create value that resonates with the senses and to contribute to a richer future for all people. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | Almost entirely product sales of formulated chemicals: inks, pigments, dispersions, adhesives, coatings and films. Service, subscription and licensing income is immaterial. Examples include the "Lioatlas" color-universal-design subscription (launched 2022) and the "Primarelink" printing-industry sharing platform (2022). Gravure cylinder platemaking (TOYO FPP) is a manufacturing service. | | Value-chain position | Mid-stream. The company buys petrochemical intermediates (naphtha derivatives, solvents, resin monomers, pigment intermediates) and sells to converters, printers, panel makers, battery-cell makers, can makers and electronics assemblers. It is vertically integrated from pigment/resin synthesis to finished ink, which it cites as a cost and quality advantage (Yuho risk section, Printing & Information). | | Customer types | Packaging converters and flexible-packaging printers; commercial, newspaper and publication printers; LCD panel and color-filter makers (largely in China); CMOS image-sensor makers; automotive LiB cell makers; beverage/food can makers; smartphone and electronics component makers; automotive and building-material manufacturers; medical/transdermal patch makers. | | Concentration | No single customer accounts for more than 10% of sales (Yuho, via ENVALITH summary). | | End-markets (company classification) | Electronics; optoelectronics; mobility; energy; packaging; medical/healthcare; building materials/living space; printing (website product taxonomy). | | Pricing dynamics | Cost-plus with lagged pass-through. Raw-material spikes compress margins until price revisions take effect. Management cited naphtha sensitivity of about JPY 150M of extra cost per JPY 1,000/KL increase (H1 FY2026 supplemental data). | ### Independent characterisation artience is best understood as a portfolio of four mid-margin specialty businesses of roughly equal size, each JPY 81–92bn in FY2025 sales. **Polymers & Coatings:** is the profit engine: 9.2% segment margin in FY2025, driven by optical PSAs for displays, can coatings and semiconductor protection sheets. **Packaging Materials:** is the volume-growth engine overseas: Turkey, India, Southeast Asia and North America. **Printing & Information:** is a cash-generating but structurally shrinking legacy business in Japan. It was rescued by price hikes, logistics alliances (including with Sakata INX) and growth in UV inks. **Colorants & Functional Materials:** holds the strategic-option value: CNT battery dispersions, CF resists and CMOS image-sensor materials. It is currently the weakest earner (2.7% margin in FY2025) because battery-materials fixed costs and impairments are absorbing the profits from display materials. The company's challenge since 2016 has been that operating profit peaked at JPY 19.2bn (FY3/2017) and fell to JPY 6.9bn in FY2022 before recovering to a record JPY 20.8bn in FY2025 (Integrated Report 2025 data; FY2025 Tanshin).

Revenue$2.3B
Employees7,880
Market CapN/A
Founded1896
Tokyo, Japan
TokaiCarbon

Tokai Carbon Co., Ltd.

Premium
Information Technology

Tokai Carbon is Japan's oldest and largest integrated carbon-materials manufacturer. It now operates as a global group with about 80% of sales generated outside Japan (Integrated Report 2025). Its portfolio covers five reporting businesses: - **Carbon black**, about 46% of FY2025 sales, for tires and rubber. **Fine Carbon:** isotropic graphite and solid silicon-carbide (SiC) focus rings for semiconductor etch equipment. **Smelting & Lining (S&L):** cathodes and furnace linings for aluminium and steel. **Graphite electrodes:** for electric-arc-furnace steelmaking. **Industrial furnaces:** and SiC heating elements. After a decade of debt-funded M&A (SGL GE 2017, Sid Richardson 2018, COBEX 2019, Carbone Savoie 2020), the group took a record ¥76.9bn of extraordinary losses in FY2024 to restructure electrodes and S&L. It returned to profit in FY2025. Under "Vision 2030" it now targets ¥500bn of sales, a 20% EBITDA margin and 12% ROIC by 2030. Current earnings momentum comes from AI-driven memory-semiconductor demand, Middle East cathode relining demand, and a tightened capital-allocation stance aimed at a price-to-book ratio above 1.0x. --- ### Company self-description In its FY2025 Yuho and earnings materials, Tokai Carbon presents itself as a carbon-materials manufacturer with six reportable segments: Carbon Black, Fine Carbon, Smelting & Lining, Graphite Electrodes, Industrial Furnaces & Related Products, and Other (friction materials and anode materials). Its long-term vision, as articulated in Vision 2030, is to contribute to a sustainable society through advanced materials and solutions. Its stated corporate identity emphasises "bonds of trust" (信頼の絆) with customers, built through more than a century of supply reliability and M&A integration. ### Business model Tokai Carbon is a vertically integrated, asset-heavy process manufacturer. It buys hydrocarbon and carbon feedstocks and processes them through capital-intensive thermal operations in plants it owns: - Carbon black feedstock oil and natural gas for furnace black. - Petroleum and needle coke and pitch for electrodes and cathodes. - Specialty cokes and silicon/carbon precursors for fine carbon and SiC. Products are sold under industrial supply contracts, typically: - annual or multi-year volume agreements with feedstock pass-through formulas (carbon black); - quarterly or semi-annual price negotiations (graphite electrodes); - project-based relining orders (cathodes); - engineered-to-order capital equipment (industrial furnaces). Head-office treasury centralises funding through a Global Cash Management System (GCMS). Operating cash flow is the main funding source; the company supplements it with bonds, commercial paper (¥60bn programme limit) and bank lines (¥84bn short-term line), per the Q1 FY2026 presentation. ### Revenue model mix | Revenue type | Approximate share | Comment | |---|---|---| | Product sales (manufactured materials) | ~95%+ | All five core segments are product businesses | | Engineered equipment and projects | ~3% | Industrial furnaces in the IF segment (¥10.7bn in FY2025) | | Licensing | Small but growing | RuC® (Ready-to-Use Cathode) licence milestone revenue recognised in Q1 FY2026 in S&L | | Services / subscription | Negligible | Machining services through US fine-carbon processors (KBR/MWI, now Tokai Carbon GS) are embedded in product sales | *Exact percentages for licensing and projects are not separately disclosed. The table is an analyst estimate built from segment data.* ### Value-chain position Tokai Carbon sits in the intermediate-materials layer: - It is upstream of tire makers (Bridgestone, Michelin, Goodyear, Sumitomo Rubber and others). - It is upstream of semiconductor equipment makers and fabs, through SiC focus rings and graphite parts for etch, CVD and crystal pulling. - It is upstream of aluminium smelters (cathode blocks, sidewalls, ramming paste) and EAF steelmakers (graphite electrodes). - It is downstream of oil refiners and coke producers, including needle-coke suppliers that are concentrated in the US, Japan and China. ### Customer types and end-markets | End-market | Segments exposed | Key customer types | FY2025 sales exposure (approx.) | |---|---|---|---| | Automotive / tires | Carbon Black, Friction | Global tire makers, rubber goods makers | ~¥155bn (CB + friction) | | Semiconductors (memory and logic etch, SiC power) | Fine Carbon | Etch-tool makers, memory fabs, SiC wafer makers | ~¥56bn | | Aluminium smelting | Smelting & Lining | Primary aluminium smelters (Middle East, Europe, Asia, Americas) | ~¥62bn | | Steel (EAF, blast furnace) | Graphite Electrodes, S&L (BF blocks) | EAF mini-mills, integrated steelmakers | ~¥38bn+ | | Electronics / energy (MLCC, LiB, power grid) | Industrial Furnaces | MLCC makers, battery-material makers, resistor users | ~¥11bn | | Batteries | Other (anode materials) | LiB makers | ~¥1.9bn, shrinking to ~¥0.2bn in FY2026E | Source: Q1 FY2026 Earnings Presentation (FY2025 quarterly segment table, adjusted). ### Independent characterisation Tokai Carbon is best understood as two businesses inside one balance sheet: 1. **A cash-generative carbon-black franchise** with structural positions in North America (Tokai Carbon CB Ltd., formerly Sid Richardson, ¥67.4bn of FY2025 sales) and Thailand (the largest single plant in the group, about 180 ktpa, being relocated to a group-owned site). 2. **A higher-multiple specialty-materials franchise**: Fine Carbon (solid SiC focus rings through 52.6%-owned Tokai Carbon Korea, plus isotropic graphite) and Industrial Furnaces (EREMA SiC heating elements, MLCC firing furnaces). The legacy steel- and aluminium-linked businesses (Graphite Electrodes and S&L) absorbed most of the capital deployed in 2017–2020. They produced the FY2024 write-downs and are now in harvest-and-fix mode. The investment debate centres on whether specialty growth plus capital-return discipline can lift ROIC from 5.8% (adjusted, FY2025) toward the 12% Vision 2030 target.

Revenue$2.2B
Employees4,436
Market CapN/A
Founded1918
Tokyo, Japan
Titanium

Titanium Tantalum Products Ltd.

Premium
Information Technology

Titanium Tantalum Products Limited was, for roughly three and a half decades, one of India's early specialist fabricators of corrosion-resistant chemical process equipment built from reactive and exotic metals — titanium, tantalum, zirconium, niobium, nickel alloys, Hastelloy, Monel, Inconel and duplex steels. Founded in Chennai in 1980 by chemical engineer Dr. R. Thangappan, it combined heavy fabrication (heat exchangers, reactors, pressure vessels, columns, tanks, pumps, thermowells) with electrochemical technology (platinised and mixed-metal-oxide titanium anodes, cathodic protection systems, on-site hypochlorite generators/electrochlorinators and marine growth prevention systems). Its customers were chlor-alkali, chemical, pharmaceutical, petrochemical, desalination, metal-finishing and pulp-and-paper plants. The business became financially distressed in the early 2010s: State Bank of India classified its loans as non-performing in November 2013. It entered insolvency in November 2017 and has been in court-supervised liquidation since June 2018, with residual assets — land, a vehicle and the TiTaN trademarks — offered at auction in 2022. --- ### What the company did (company's own description) No annual report is publicly accessible. The closest equivalent to an "own description" is the company profile it maintained on its legacy website and replicated across trade directories. In that profile, the company describes itself as an ISO 9001:2008 certified, multi-product enterprise. It claims leadership in the design, manufacture, erection, commissioning and servicing of exotic-metal chemical equipment since 1981. It lists its application industries as chemical and electrochemical, electroplating and metal finishing, petroleum and petrochemicals, desalination and waste treatment, food and paper, and pharmaceuticals (EnggPro). A second passage in the same profile presents TiTaN as a process developer and manufacturer of electrochemical cells and systems, serving life sciences and industrial/municipal water and wastewater since 1980 (EnggPro). The company's itemised offering list includes design, manufacture and refurbishment of heat exchangers, pressure vessels, reactors, tanks, pumps, industrial valves, blowers, columns and towers, pipes and fittings, thermowells, heating and cooling coils, and fasteners. It also lists cathodic protection anodes, electrodes for electrochemical applications, on-site hypochlorite generators, MGP (marine growth prevention) systems, and electrolysers for chlor-alkali and chlorate applications (EnggPro; Rigzone). ### Independent characterisation Analytically, TiTaN operated two related but economically distinct businesses under one roof. The first was engineered-to-order exotic-metal process equipment fabrication. This is a project business. Revenue is lumpy and milestone-based, working capital is heavy (expensive titanium/zirconium/tantalum plate and tube must be bought before billing), and margins depend on welding and fabrication competence in reactive metals. Those metals must be welded under inert-gas shielding and are unforgiving of contamination. Customers buy on specification, code compliance (pressure-vessel codes) and track record. Competitive intensity is high from both large Indian engineering groups and small local fabricators. The second was electrochemical electrodes and systems: platinised titanium/niobium anodes, mixed-metal-oxide (MMO/DSA-type) coated anodes, impressed-current cathodic protection (ICCP) anodes, electrochlorinators and MGPS. This business has more product-like characteristics. It includes repeat demand from anode recoating and replating, smaller ticket sizes, and higher gross margins on coatings. However, it competes directly against global technology owners, most prominently the De Nora group, whose Indian subsidiary is listed. The company also listed tantalum repair kits (for glass-lined vessel repair) among its products (ExportHub). ### Business and revenue model | Dimension | Characterisation | Evidence basis | |---|---|---| | Product vs. service mix | Predominantly product (fabricated equipment, anodes, systems); service component in erection, commissioning, refurbishment and anode recoating | Company profile lists "design, manufacturing, erection/commissioning and services" | | Subscription / licensing | None identified | No evidence in sources | | Pricing model | Project-based quotation for engineered equipment; unit pricing for anodes/components | Industry norm; company pricing not publicly disclosed | | Value-chain position | Midstream converter/fabricator: buys mill products (plate, sheet, tube, rod) of reactive metals and precious-metal coating precursors; sells finished equipment to process-plant owners and EPC contractors | Product list | | Customer types | Chemical, chlor-alkali, pharmaceutical, petrochemical, metal-finishing, desalination, water treatment, pulp & paper, marine/power (for MGPS/electrochlorination) | Company profile | | Geographic reach | Domestic India plus exports (holder of own export licence; claims "global" market position) | ExportHub; company profile | | Line of business (directory classification) | Manufacturer, exporter, distributor | Rigzone | ### Current state of the business Since 12 June 2018, the business has been discontinued. The liquidator informed the Employees' Provident Fund Organisation (EPFO) in writing on 4 April 2019 that, once the liquidation order was passed, the business would be discontinued. He also stated that all officers, employees and workmen were discharged from the date of the order (NCLAT judgment, para 17). After 12 June 2018 the liquidator engaged some workers on an ex-gratia basis, solely to complete pending orders on hand and for liquidation-related work (NCLAT judgment, para 37/23). There is no evidence of any going-concern sale of the business. The 2022 auction lots consisted of vacant land, a motor vehicle and trademarks, which implies the operating plant was either disposed of earlier or realised separately.

RevenueN/A
Employees33
Market CapN/A
Founded1980
Chennai, India

Page 93 of 482

1…929394…482

Page 93 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo